Consequences of persistent antigen presentation following administration of HIV-1-derived lentiviral vectors by Arce Vargus, F.
 
 
 
 
 
 
 
 
 
 
 
Consequences of persistent antigen 
presentation following administration of 
HIV-1-derived lentiviral vectors 
 
 
 
 
 
 
 
 
 
 
 
 
Frederick Arce Vargas 
 
 
 
 
 
Thesis submitted to the University College of London 
for the degree of Doctor of Philosophy 
 
2010 
 
 
 
 
Division of Infection and Immunity 
University College of London       2 
 
DECLARATION 
 
 
 
 
 
 
 
 
I,  Frederick  Arce  Vargas,  confirm  the  work  presented  in  this  thesis  is  my  own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
       3 
ABSTRACT 
 
Lentiviral vectors (LVs) are promising tools for in vivo gene delivery, either 
to  correct  genetic  defects  or  for  vaccination.  Intravenous  administration  of  LVs 
results in  stable transduction and expression of the transgene in antigen presenting 
cells (APCs) from the spleen. Therefore, it was decided to investigate the reasons for 
and the consequences of sustained antigen expression in these cells after systemic in 
vivo administration of LVs. Intravenous injection of a LV encoding green fluorescent 
protein (GFP) resulted in transduction of lymphocytes, macrophages and all subsets 
of  dendritic  cells  (DCs)  in  the  spleen,  detected  5  days  later.  In  the  case  of 
macrophages and DCs, the percentage of transduced cells increased between 5 and 
30 days after injection. The transduction of dividing precursors contributes to the 
persistence  of  the  transgene-expressing  DCs,  as  shown  by  BrdU  incorporation.  
Expression  of    ovalbumin  (OVA)  resulted  in  a  reduced  number  of  transgene-
expressing cells after 30 days. However, the remaining transduced cells stimulated 
proliferation and activation of OVA-specific CD8
+ T cells up to 3 months after LV 
administration, in spite of a reduction in the activation status of transduced DCs over 
time. Mice also maintained cytolytic activity against OVA-pulsed targets following a 
single immunisation. In conclusion, this thesis shows that LVs can transduce DCs 
and macrophages, leading to persistent antigen expression. These modified APCs are 
functional and capable of activating T cells. Therefore, LVs can be used as tools for 
persistent genetic modification of APCs, opening the opportunity for their use in 
long-term immunomodulation.       4 
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CHAPTER 1 
1. INTRODUCTION  
Vaccines  are  valuable  tools  for  the  prevention  and,  potentially,  for  the 
treatment  of  infectious  diseases  and  cancer.    Despite  its  many  successes—as  
highlighted by the eradication of smallpox—vaccination has not yet proved effective 
against a wide variety of conditions. Alternative immunisation strategies are needed 
especially for chronic infections or malignant diseases, where an inadequate immune 
response must be reactivated. 
The  ideal  vaccines  should  assure  optimal  antigen  delivery  to  professional 
antigen presenting cells (APCs) in the right activation context, in order to induce 
potent primary and memory immune responses with minimal side effects. This has 
been  typically  achieved  with  preparations  of  protein  antigens  together  with 
adjuvants. The APCs play a pivotal role in this process by bridging the adaptive and 
innate immunity. 
  In recent years, genetic modification of APCs has transformed vaccine design 
and development. This approach is based on the delivery of antigen genes into APCs, 
which process and present them on major histocompatibility complexes (MHC) after 
their transcription and translation. Increasing knowledge in the biology of APCs and 
the improvement of gene therapy techniques have made of this a promising strategy. 
In the past few decades, most of the interest has concentrated on dendritic cells 
(DCs), one of the most potent APCs (Steinman & Banchereau 2007). Hence, many 
of  the  studies  concerning  genetic  modification  of  APCs  have  focused  on  DCs, 
although other professional APCs also play an important role.  
Gene delivery to DCs, both in vitro and in vivo, has been achieved with viral 
and non-viral vectors. Among the latter, recombinant lentiviruses (LVs) have been 
shown to generate a stable and high expression of the antigen gene. At the same time, 
they convey a series of advantages that make them good candidates for clinical use in       14 
immunisation,  as  will  be  further  discussed.  This  thesis  will  explore  the  immune 
consequences resulting from antigen-gene delivery using LVs. Due to the fact that 
LVs can integrate into the host’s genome, this project will focus on the effects of 
stable  antigen  expression  in  APCs  after  systemic  in  vivo  administration  using  a 
murine model.   
 
1.1.  Genetic modification of dendritic cells as a strategy for 
immunisation 
Genetic modification of DCs is an attractive approach for immunisation since 
it  results  in  superior  antigen  processing  as  compared  with  other  vaccination 
strategies. One of its advantages is that the antigens are produced in their native 
conformation and then processed by the DC. This favours a multispecific immune 
response.  In  addition,  the  identification  of  specific  immunogenic  peptides  is  not 
completely necessary (Germain & Margulies 1993; Esslinger et al. 2002; Collins & 
Cerundolo 2004). 
Genetic modification of DCs can be performed in vitro and in vivo. In the 
first method, DCs are generated ex vivo from blood or bone marrow precursors using 
specific cytokine combinations. Autologous DCs are then genetically modified and 
re-injected in the donor. This approach has been especially useful in understanding 
DC biology and function, and effective enough to justify its testing in the clinic. 
However,  this  process  is  costly  and  laborious  since  it  requires  specific  vaccine 
preparation in each individual case. Direct in vivo administration of gene vectors 
bypasses  this  problem  because  the  same  vector  preparation  can  be  applied  to 
different  recipients.  Nevertheless,  this  approach  also  implies  a  risk  of  ‘vector 
spillage’ and transduction of other cells besides the desired targets.  To overcome 
this limitation, several strategies have been developed to engineer specific targeting 
to particular cell types (Frecha et al. 2008). 
A variety of gene vectors have been used to transduce DCs (Breckpot et al. 
2004).  These can be grouped in two broad categories: viral and non-viral vectors.       15 
1.1.1. Non-viral vectors 
  Nucleic acids encoding  antigen  genes  can be delivered directly into DCs. 
Both DNA and mRNA have been used with this purpose, exhibiting a good safety 
profile and minimal risk of insertion in the host’s genome. Besides, nucleic acids 
production is straightforward and can be scaled-up at low cost (Breckpot et al. 2004; 
Kutzler & Weiner 2008).  However, difficulties in vector delivery, low transgene 
expression levels and limited success in clinical trials have inhibited their use.    
1.1.1.1.  DNA vaccines 
DNA  vaccines  that  encode  specific  antigen  genes  have  been  used  with 
relative success in pre-clinical studies in generating immunity against multiple types 
of  cancer  (Rice  et  al.  2008)  as  well  as  infectious  diseases,  such  as  human 
immudeficiency virus (HIV) (Center et al. 2009), influenza (Szécsi et al. 2009), and 
malaria (Daubersies et al. 2008). The gene products are presented to T cells by APCs 
that have been transfected directly or have picked up exogenous antigen shed from 
other cell types, or phagocytosed it from dead cells. This generates both humoral and 
cellular immune responses (Kutzler & Weiner 2008).   
An important advantage of DNA vaccines is that they also contain pathogen-
associated  molecular  patterns  that  stimulate  innate  immunity  through  Toll-like 
receptors  (TLRs).  Particularly,  engagement  of  TLR-9  by  hypomethylated  CpG 
motifs present in DNA has been involved in DC activation (Klinman 2006). TLR-9 
is expressed both in conventional and plasmacytoid DCs in mice, but only in the 
latter in humans. However, Tlr9
-/-  mice can be effectively immunised  with DNA 
vaccines,  indicating  that  this  is  not  the  only  immunogenic  mechanism  involved 
(Spies et al. 2003).  DNA also activates DCs via its recognition by retinoic acid-like 
inducible gene-I (RIG-I) receptors and nucleotide-binding oligomerisation domain 
(NOD)-like receptors (Koyama et al. 2009). 
  A caveat of DNA vaccination is its difficult delivery to APCs. Transfection of 
ex vivo-generated DCs is inefficient, reaching not more than 12% of the cells even 
when using electroporation (van Tendeloo et al. 1998). To overcome this problem, 
particle-mediated  delivery,  gene  gun  and  intramuscular  injection  with  or  without       16 
electroporation have been applied in vivo with variable results (Fuller et al. 2006; 
Rice et al. 2008). 
  Multiple  clinical  trials  with  DNA  vaccines  against  a  variety  of  infectious 
agents and cancers have demonstrated their safety, but failed to show high levels of 
vaccine-specific  immunity  (Kutzler  &  Weiner  2008).  Consequently,  several 
strategies to improve their effectiveness are being developed. Examples include the 
using ‘prime-boost’ protocols in combination with other vectors (Peters et al. 2007),  
or co-expression of adjuvants (e.g., fragment C of tetanus toxin) to activate DCs, or 
direct expression of co-activators (e,g, CD86) (Rice et al. 2008).  
1.1.1.2.  mRNA vaccines 
An  alternative  vaccination  strategy  is  the  use  of  antigen  gene-encoding 
mRNA. The principle of mRNA immunisation is similar to that of DNA, although 
expression is transient as these molecules are degraded by cellular ribonucleases. 
mRNA activates APCs through recognition by TLR-7 in mice and TLR-8 in humans 
(Heil et al. 2004; Diebold et al. 2004). It can be delivered directly in vivo either as 
‘naked’ molecules, in liposomes, in particles with the gene gun and in the form of 
virus-derived replicative RNA (Pascolo 2004).  
Another  option  is  ex  vivo  transfection  of  DCs.  In  contrast  to  DNA, 
incorporation of mRNA into ex vivo-generated DCs is more efficient; up to 81% and 
62% of human and murine DCs, respectively, can be transfected (Dullaers et al. 
2004).    Passive  diffusion,  lipofection,  electroporation  and  transferrin  receptor 
(CD71)-mediated endocytosis have been effective in delivering total mRNA from 
tumoral cells or molecules encoding specific antigens (Breckpot et al. 2004). 
Using  this  technique,  both  humoral  and  cellular  responses  have  been 
generated  against  tumour-associated  antigens  (TAAs),  as  well  as  antigens  from 
infectious  agents,  including  HIV,  human  papilloma  virus  and  influenza,  among 
others.  Results have been promising so far and several trials have shown partial 
clinical response (Pascolo 2004; Grünebach et al. 2005)).  
Co-transfection  with  mRNA  encoding  co-stimulatory  molecules  is  being 
tested to enhance these vaccines. For example, Bonehill et al. (2009) have reported a       17 
better  immune  response  by  DC  co-transfection  with  mRNA  cassettes  encoding 
CD40,  CD70  and  a  constitutively  active  form  of  Toll  like  receptor  4  (TLR4), 
together with melanoma-associated antigens.  However, one of the major concerns of 
mRNA-based  vaccines  is  that  the  antigen  will  only  be  expressed  transiently. 
Although this characteristic favours its safety, it can also impair its efficacy. 
 
1.1.2. Viral vectors for vaccination 
  More than half of the vectors used in clinical gene therapy trials today are 
recombinant  viruses  (Clinical  Trials  Worldwide,  2009,  in  www.wiley.co.uk/ 
genetherapy/clinical/). Different viral vectors have been used to transduce DCs in 
vitro and in vivo, resulting in effective immunisation against infectious diseases and 
cancer.  It  has  also  been  shown  that  viral  transduction  is  more  effective  for  the 
induction of tumour-reactive CD8
+ and CD4
+ T cells than DC transfection with DNA 
or mRNA (Lotem et al. 2006).  
The most commonly viral vectors employed for gene delivery to DCs are 
adenoviruses, adeno-associated viruses, poxviruses, herpes viruses, oncoretroviruses 
and lentiviruses. Their main characteristics are summarised in Table 1.1  
 
 
Table 1.1. Key features of viral vectors used for transduction of DCs.
 
 
Parental 
virus  Genome  Envelope  Packaging 
capacity  Main advantages  Main disadvantages  Immunisation 
clinical trials 
Adenovirus  dsDNA  No  30 kb  -High titers 
-Episomal 
-High transduction efficiency of 
APCs  
-Anti-vector immunity  Yes 
Poxvirus  dsDNA  Yes  30 kb  -High titers 
-Cytoplasmic translation 
-Moderate transduction efficiency 
of APCs 
-Anti-vector immunity 
-Safety concerns in immune- 
compromised hosts 
Yes 
Adeno-
associated 
virus 
ssDNA  No  ~5 kb  -Non-pathogenic parental virus 
-Episomal 
 
-Limited packaging capacity 
-Anti-vector immunity 
No
a 
Herpes virus  dsDNA  Yes  40 kb 
150 kb in 
amplicons 
-High titers 
-High packaging capacity 
-Anti-vector immunity (?) 
 
No 
Oncoretrovirus  ssRNA+  Yes  8-10 kb  -Sustained gene expression  -Risk of insertional mutagenesis 
-Cell-cycle dependent 
No
a 
Lentivirus  ssRNA+  Yes  8-10 kb  -Sustained gene expression 
-No anti-vector immunity 
-Risk of insertional mutagenesis  No
a 
 
aUsed in clinical trials for gene replacement therapy.  
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1.1.2.1.  Adenoviral vectors 
  Adenoviridae is a family of non-enveloped viruses that have a ~30-35 kb 
double-stranded linear DNA genome contained within an icosahedral capsid. They 
infect various species of vertebrates including humans, where 54 serotypes, grouped 
in 7 species, have been identified (Lasaro & Ertl 2009). 
  Their  genome  contains  early  (E)  and  late  (L)  genes.  First  generation 
adenoviral vectors (AVVs) are produced by substituting regions E1 and/or E3 by an 
expression  cassette.    E1  gene  products  have  regulatory  functions  and  are 
indispensable for viral replication. Therefore, they have to be provided in trans for 
vector production. E3 gene products subvert the host’s immune responses and are 
dispensable  for  viral  replication  (Danthinne  &  Imperiale  2000).  Vectors  with 
additional  deletions  in  early  genes  have  been  engineered  to  reduce  the  immune 
response to the vector, prolong antigen expression and improve safety.  This is the 
case of second generation AVVs, which have further deletions in E2 and/or E4, and 
‘fully gutted’ (or ‘gutless’) vectors, where all the viral coding sequences have been 
removed (Ehrhardt & Kay 2005).  
AVVs  efficiently  transduce  DCs  and  stimulate  the  innate  immune  system 
through several mechanisms.  Most of the immunisation studies have been carried 
out with E1- or E1/E3-deleted vectors derived from serotypes 2 or 5. In pre-clinical 
models, these vectors have been shown to induce potent transgene-specific T (C8
+ 
and  CD4
+)  and  B  cell  responses  (Lasaro  &  Ertl  2009).    However,  their  main 
limitation  is  the  high  immunogenicity  of  the  viral  particle.  This  hampers  the 
magnitude  of  the  desired  immune  response  to  the  transgene  by  reducing  its 
expression and precludes the use of repeated immunisations with the same vector 
(Sakurai et al. 2008). Life-threatening systemic inflammatory reactions have also 
been reported in some patients (Thacker et al. 2009).  
In  spite  of  this,  AVV  vaccines  have  been  developed  for  the  treatment  of 
different diseases and tested in several clinical trials, although with disappointing 
results.  For example, in the phase IIb STEP clinical trial, immunisation with an 
AVV-5 encoding several antigens of HIV-1 did not decrease the rates of infection or       20 
post-infection viral load. Furthermore, a trend towards increased HIV-1 acquisition 
was observed in vaccine recipients, particularly in individuals with pre-existing anti-
AVV-5 neutralising antibodies. The underlying mechanisms to explain this apparent 
increased susceptibility remain unknown (Buchbinder et al. 2008). 
Several modifications in vector design are being developed to improve AVV 
safety  and  efficiency  as  vaccine  vectors,  especially  to  overcome  the  anti-vector 
immunity. These include the use of rare human or chimpanzee serotypes and co-
expression of antigens and immunomodulators. Structural modifications of the viral 
particle  have  also  been  employed  to  target  the  vector  to  specific  cells  and  to 
eliminate the capsid epitopes recognised by neutralising antibodies (Lasaro & Ertl 
2009; Thacker et al. 2009).    
1.1.2.2.  Poxvirus-derived vectors 
  Members of the Poxviridae family have large double-stranded DNA genomes 
that  encode  several  hundred  proteins,  many  of  which  are  not  essential  for  viral 
replication and can be deleted or replaced by large inserts of foreign DNA (up to ~30 
kb).  Their replication occurs in the cytoplasm using the translation machinery of the 
infected cell, without integration in the host’s genome.  Poxvirus-derived vectors are 
stable, easy to manufacture and administer and have a broad tropism (Gómez et al. 
2008).  
Two attenuated strains derived from vaccinia virus have been safely used as 
gene vectors.  Modified vaccinia virus Ankara (MVA) was derived from a smallpox 
vaccine strain after serial passage in primary chicken embryo fibroblasts. New York 
vaccinia  virus  attenuated  from  Copenhagen  (NYVAC)  was  also  derived  from  a 
smallpox vaccine strain in which 18 open reading frames were deleted from the virus 
genome. In both cases, the viruses have lost their replication capacity and part of 
their broad tropism in mammalian cells, while keeping their ability to drive high-
level gene expression. An expression cassette can be inserted by recombination in 
sites  of  naturally  occurring  deletions  or  in  other  loci,  such  as  those  encoding 
thymidine kinase or haemagglutinin (Drexler et al. 2004).        21 
Poxvirus  vectors  can  efficiently  transduce  DCs  and  elicit  humoral  and 
cellular immune responses. They mimic viral infections and therefore stimulate the 
innate immune system. The loss of immunomodulatory genes from the parental virus 
accounts  for  their  strong  immunogenicity  (Gómez  et  al.  2008).  Both  MVA  and 
NYVAC have been shown to induce protective immunity. However, while the first 
tends  to  induce  both  CD8
+  and  CD4
+  T  cell  responses,  the  latter  predominantly 
induces a CD4
+ T cell response (Mooij et al. 2008).  
An  important  drawback  in  their  use  is  that  the  expressed  viral  proteins 
compete  with  the  transgene-derived  epitopes.  This  hampers  transgene-specific 
cytotoxic T lymphocyte (CTL) responses, especially after repeated immunisations, 
and can explain the failure to generate comparable T cell responses to those observed 
in  natural  viral  infections  (Smith  et  al.  2005).  To  avoid  this  problem,  combined 
prime/boost protocols using MVA and DNA vaccines or other recombinant viruses 
have been employed. 
  MVA  and  NYVAC  have  been  studied  in  multiple  pre-clinical  assays  as 
vaccines  against  infectious  agents  and  cancer,  showing  different  degrees  of 
protection in most models. Phase I and II clinical trials with MVA-based vectors 
delivering antigens against infectious agents (e.g., HIV-1, malaria, tuberculosis) or 
TAAs have demonstrated the safety of these vectors, but the clinical outcomes have 
been variable (Gómez et al. 2008). Phase III trials are currently open (Gene Therapy 
Clinical Trials Worldwide, 2009, in www.wiley.co.uk/genetherapy/clinical/). 
  Other poxviruses, such as recombinant avipox (fowlpox and canarypox), have 
also  been  tested  for  immunisation.  Fowlpox-derived  vectors  have  been  used  in 
clinical  trials  as  a  booster  following  immunisation  with  vaccinia  virus  in  the 
treatment  of  advanced  cancer,  showing  a  good  safety  profile  and  generation  of 
specific  CTLs  (Gulley  et  al.  2008;  Lechleider  et  al.  2008).  Canarypox  vectors 
encoding tumoral antigens (Spaner et al. 2006) or HIV epitopes (Russell et al. 2007) 
have shown poor immunologic responses. Expression of co-stimulatory molecules 
together with the antigen is being assayed to overcome this limitation (Liu et al. 
2008).       22 
1.1.2.3.  Adeno-associated viral vectors 
  Recombinant adeno-associated virus (AAV), a nonenveloped parvovirus, has 
also been extensively used as a gene vector. This virus requires the functions of a 
helper  virus  (usually  adenovirus  or  herpesvirus)  for  replicative  infection.  In  its 
absence,  AAV  replication  is  limited  and  it  can  establish  latency  by  specific 
integration into the chromosomal locus 19q13.4 (Schultz & Chamberlain 2008). Its 
main advantage is that the parental virus is non-pathogenic in humans. 
AAV has a single-stranded DNA genome with two coding regions flanked by 
inverted  terminal  repeats  (ITRs),  which  have  a  series  of  regulatory  functions.  In 
AAV-derived vectors, the coding regions are replaced by foreign genes of up to ~5 
kb.  Despite its limited packaging capacity, strategies such as trans-splicing and self-
complementary  AAVs  have  been  developed  to  express  larger  proteins  (McCarty 
2008). In the actual constructs, the regions necessary for genome integration have 
been removed, so the vector persists in the nucleus as extrachromosomal elements 
(Daya & Berns 2008). 
Several  AAV  serotypes  have  been  used  as  vectors,  although  most  of  the 
studies have been based on AAV-1 and AAV-2. These vectors can transduce DCs 
with  variable  efficiencies  and  induce  specific  CTL  responses  (Mahadevan  et  al. 
2007; Veron et al. 2007; Yu et al. 2008).   AAV-based vectors have been used in 
gene therapy clinical trials. One  of the observed limitations is the prevalence of 
neutralising antibodies against the vector in some human populations (Daya & Berns 
2008).  
1.1.2.4.  Herpes virus 
  Herpes  simplex  virus  (HSV)  is  an  enveloped  virus  with  a  linear  double-
stranded DNA genome that encodes more than 80 viral proteins. The wild-type virus 
can produce a lytic infection or persist in a latent stage, whereby the viral genome 
persists  as  an  epichromosomal  form  with  minimal  transcriptional  activity  in  the 
nucleus  of  the  host  cell.  In  replication-defective  vectors,  mutation  or  deletion  of 
essential genes renders the virus unable to grow except in transformed cell lines, 
where these elements are provided in trans. These deleted genes can be replaced by       23 
foreign DNA of up to ~40 kb. In amplicon vectors, the HSV-1 particles carry a 
concatemeric form of a plasmid DNA instead of the viral genome, with no viral 
coding sequences and multiple copies of the same or different transgenes (Marconi et 
al. 2008). 
HSV  vectors  efficiently  transduce  DCs  (>90%),  induce  their  partial 
maturation without affecting their viability and elicit strong CTL responses (Chiu et 
al.  2009).  For  example,  replication-defective  HSV-1  encoding  simian 
immunodeficiency  virus  (SIV)  antigens  resulted  in  partial  protection  against  a 
challenge  with  SIV  in  macaques  (Murphy  et  al.  2000).  However,  their  clinical 
application for antigen gene delivery has not yet been evaluated. 
  A potential drawback of HSV-based vectors is the presence of pre-existing 
immunity against the parental virus, although this issue is controversial. While a 
study has shown that the vectors can induce immune responses even in the presence 
of pre-existing host immunity (Brockman & Knipe 2002), another has demonstrated 
that they could be hampered depending on the route of inoculation (Lauterbach et al. 
2005). 
1.1.2.5.  Retrovirus 
  Retroviruses belong to the family Retroviridae, a group of RNA viruses that 
replicate through a dsDNA intermediate that integrates into the host genome. Once 
integrated, the viral RNA can be transcribed during the life of the cell resulting in 
long-term  gene  expression.  An  advantage  of  retroviral  vectors  is  the  absence  of 
expression of most viral proteins, which reduces anti-vector immune responses.  
Because  of  historical  and  practical  reasons,  the  most  commonly  used 
retroviral  vectors  derive  from  Moloney  murine  leukaemia  virus  (MLV).  These 
vectors  are  difficult  to  produce  in  titers  comparable  to  other  vectors  and  only 
transduce dividing cells because they require disruption of the nuclear membrane to 
integrate into the host’s DNA (Roe et al. 1993).  This would potentially limit the 
transduction of DCs, which are generally regarded as terminally-differentiated, non-
dividing cells. However, transduction of monocyte-derived DCs using MLV vectors 
has  been  reported,  with  an  efficiency  of  30-60%  (Aicher  et  al.  1997).    Another       24 
approach  relies  on  the  transduction  of  dividing  CD34
+  haemopoietic  precursors, 
which can then be differentiated into DCs.  This strategy has resulted in transduction 
of 40-70% of CD34
+-derived DCs (Heemskerk et al. 1999; Movassagh et al. 1999). 
  The cell-cycle dependence of retroviral vectors has been circumvented with 
the use of lentiviral vectors (LVs), derived from other members of the Retroviridae 
family.    LVs  have  the  key  ability  to  transduce  non-dividing  cells,  resulting  in 
efficient gene delivery to DCs. This has led to promising results in the fields of gene 
therapy and genetic immunisation.  
1.2.  Lentivirus 
  Lentiviruses are complex retroviruses of the genus Lentiviridae that cause 
several  slow-onset  diseases.  They  have  been  extensively  studied  because  of  the 
impact  that  HIV,  a  member  of  this  genus,  has  had  in  public  health  in  the  past 
decades.  
LVs  have  been  engineered  to  become  efficient  and  safe  gene  transfer 
vehicles. As compared with other gene delivery technologies, they convey several 
advantages that have overcome some of the limitations of other vectors: (1) they can 
transduce  non-dividing  cells,  (2)  the  elimination  of  all  dispensable  viral  proteins 
from the vector genome minimises their cellular toxicity and immunogenicity, (3) the 
exposure of the host to the parental viruses is low, reducing the possibility of pre-
existing anti-vector immunity and (4) LVs can be pseudotyped with different viral 
envelopes, providing more stability to the viral particle, the possibility of targeting 
specific cells and the potential to repeat immunisations using different envelopes 
(Kim et al. 2005; Loisel-Meyer et al. 2009). 
  LVs have been derived from equine infectious anaemia virus (Olsen 1998), 
SIV (Stitz et al. 2001)  and feline immunodeficiency virus  (Sakurai et  al. 2008). 
However,  most  studies  regarding  the  use  of  LVs  for  immunisation  have  been 
performed with vectors derived from HIV-1, which normally infects DCs.  
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1.2.1. HIV-1 structure and life cycle 
  HIV-1 virions are enveloped spherical particles of 100-120 nm in diameter. 
The viral envelope is composed of a lipid bilayer, viral envelope glycoproteins and 
some cellular proteins (Fig. 1.1A). The envelope surrounds a truncated cone-shaped 
capsid  (termed  core)  made  of  capsid  protein  that  encloses  two  genomic  RNA 
molecules complexed with nucleocapsid proteins, viral proteins (protease, reverse 
transcriptase, integrase) and some cellular factors. The core is further enclosed by a 
layer of matrix protein present under the viral envelope (Hughes 1997).  
1.2.1.1.  Genomic organisation   
The HIV-1 genome consists of two identical 9.2 kb single-stranded positive 
RNA molecules. Its organisation is shown in Figure 1.1B. Four main regions can be 
distinguished: 
(1)  The long terminal repeats (LTRs) are important regulatory regions that 
flank the 5’ and 3’ ends of the genomic RNA. After reverse transcription, each LTR 
consists of 3 segments: unique 3 (U3),  repeat (R) and  U5.  The U3 region contains 
binding  sites  for  cellular  transcription  factors.  The  R  segment  includes  the 
transactivation response element (TAR), implicated in Tat-mediated transactivation 
(Berkhout & Jeang 1992; Richter et al. 2002). 
(2) The Gag-pol gene encodes two polyprotein precursors. Gag polyprotein 
(p55) is proteolytically processed into 3 viral structural proteins: matrix (p17), capsid 
(p24) and nucleocapsid (p7), and the polypeptide p6. A -1 ribosomal frameshift leads 
to translation of Gag-pol that additionally encodes the viral enzymes necessary for 
replication: protease, reverse transcriptase (RT)/RNase H and integrase (Sierra et al. 
2005).  
(3) The env gene encodes the gp160 polypeptide precursor, which consists of 
transmembrane  gp41  and  surface  gp120  subunits.  Together  with  a  lipid  bilayer 
derived from the cell membrane, these glycoproteins form the viral envelope that       27 
mediates virus entry to the cell by interaction with receptors and co-receptors (Sierra 
et al. 2005). 
(4) Six additional genes are present in the  HIV-1  genome: the regulatory 
genes  Tat  and  Rev,  and  the  accessory  genes  Nef,  Vpu,  Vpr  and  Vif,  which  have 
different functions that will be mentioned later. 
1.2.1.2.  Life cycle 
The HIV life cycle can be divided into two phases. The early phase begins 
with the attachment of the virus to the cell and finishes with the integration of the 
viral  genome  into  the  DNA  of  the  host  cell.  The  late  phase  starts  with  the 
transcription of viral genes and continues until new virions are released. The main 
steps of each phase are shown in figure 1.2A.   
1.2.1.2.1.   Cell entry 
HIV-1  cell  entry  is  a  complex  multi-step  process  that  starts  with 
proteoglycan-dependent adsorption of the virus to the cell. In DCs, adsorption is also 
mediated by cell surface lectins, such as DC-SIGN. Following this initial binding 
step,  HIV-1  envelope  glycoproteins  (gp120  and  gp41)  recognise  their  primary 
receptor, CD4.  This restricts the tropism of the virus to CD4
+ T cells, monocytes, 
macrophages and DCs.  Binding of gp120 and CD4 triggers conformational changes 
in these molecules and recruitment of co-receptors, CXCR4 and CCR5 (Feng et al. 
1996).    This  results  in  further  conformational  changes  leading  to  gp41-mediated 
fusion of the viral envelope with the cell membrane. 
1.2.1.2.2.  Uncoating and reverse transcription 
  After  membrane  fusion,  the  viral  core  is  released  into  the  cytoplasm  and 
disassembled. The viral RNA, associated with several viral and cellular proteins, is 
released in the form  a  reverse transcription complex, in which the viral RNA is 
reverse  transcribed  to  double-stranded  DNA  by  the  virion-packaged  reverse 
transcriptase. The trigger for reverse transcription is not completely understood, but       28 
the  high  concentration  of  cytoplasmic    deoxyribonucleotides    seems  to    play  a 
significant role (Goff 2001). The reverse transcriptase presents additional RNAse H 
activity, which degrades the viral template RNA as it is reverse transcribed. 
It  is  worth  noting  that  the  host  cells  present  several  anti-retroviral 
mechanisms, such as the antiviral APOBEC3G protein. This interferes with reverse 
transcription by inducing deamination of cytidine bases in the minus DNA strand. In 
the case of HIV-1, the accessory protein Vif, which is incorporated within the viral 
core, counteracts this effect  by reducing APOBEC3G incorporation into the virions 
and inducing its ubiquitination and subsequent degradation (Sheehy et al. 2003).  
1.2.1.2.3.  Nuclear import and integration 
The completion of reverse transcription results  in the formation of a  pre-
integration complex, which is actively transported from the cytoplasm to the nucleus 
through  the  nuclear  pore  complexes.  Consequently,  in  contrast  with  other 
retroviruses,  HIV-1  does  not  require  disruption  of  the  nuclear  membrane  during 
mitosis to reach the host cell DNA. Although the mechanism of nuclear import is still 
not clear, it has been shown that four different components of the pre-integration 
complex participate in the transport through the nuclear pore:  the integrase, the 
matrix protein, Vpr and the viral DNA. The first three contain nuclear localisation 
signals and interact with components of the nuclear pore complex. Vpr in addition 
has been proposed to mediate an unconventional mode of nuclear entry by disruption 
of the nuclear envelope. However, studies so far have been controversial (Suzuki & 
Craigie 2007; Nisole & Saïb 2004).  
A  triple-stranded  DNA  flap  also  seems  to  participate  as  a  nuclear  import 
signal  by  an  undefined  mechanism.  This  structure  originates  during  reverse 
transcription,  when  DNA  synthesis  is  initiated  concomitantly  from  a  central 
polypurine  tract  (cPPT)  and  a  3’  PPT,  resulting  in  a  99  nucleotide-long  strand 
overlap.  In fact, the presence of cPPT in HIV-based vectors significantly enhances 
nuclear entry in quiescent cells (Firat et al. 2002). 
  Once  in  the  nucleus,  integration  into  the  host  DNA  is  catalysed  by  the 
integrase in a two-step process. The first stage is known as 3’ processing and takes       29 
place in the cytoplasm. Here the integrase cleaves a dinucleotide adjacent to the 
attachment (att) sites at the ends of the viral DNA, which exposes recessed 3’OH 
groups.  In  the  second  step,  called  strand  transfer,  the  integrase  catalyses  a 
nucleophilic attack to phosphodiester bonds in the target DNA and ligates the viral 
DNA. Finally, host DNA repair enzymes remove the two nucleotide overhangs and 
repair  the  gaps  in  the  DNA  (Engelman  et  al.  1991).    The  HIV-1  genome 
preferentially  integrates  in  genes  highly  transcribed  by  RNA  polymerase  II,  as 
studied by Schröder et al. (2002). 
1.2.1.2.4.  Retroviral gene expression 
  HIV-1  early  gene  expression  starts  at  the  5’LTR  using  the  cellular 
transcriptional  machinery.  The  LTR  U3  region  contains  binding  sites  for  several 
transcription factors (e.g., NF￿B) which transactivate the viral promoter, resulting in 
basal transcription of the viral genome. Viral transcription begins from nuclear pre-
integration  viral  forms  (linear,  1-LTR  and  2-LTR  circles)  and  continues  after 
incorporation of the provirus to the host’s genome (Wu 2004). However, elongation 
of the nascent mRNA is inefficient at this stage. During early gene expression, Tat is 
accumulated and then binds to the transactivation response element (TAR) in the R 
region  of  the  LTR  and  to  other  cellular  transcriptional  co-activators.  Thus,  Tat 
recruits transcription elongation factors to the HIV-1 promoter and also interacts with 
mRNA capping proteins, all of which stabilises nascent RNA transcripts (Harrich et 
al. 1997). 
1.2.1.2.5.  Splicing and nuclear export 
Transcripts from HIV-1 undergo multiple alternative splicing events. In the 
early phases, only multiply-spliced mRNAs are produced, resulting in expression of 
Tat, Nef and Rev. Nuclear export of full-length viral genomic RNA is, however, 
required  for  the  expression  of  Gag-pol  proteins  and  for  its  packaging  into  new 
virions. This is achieved when there is enough expression of Rev, which is critically 
important  for  the  nuclear  export  of  full-length  and  incompletely-spliced  HIV-1 
transcripts.  Rev  recognises  the  Rev-responsive  element  (RRE),  an  RNA  element       30 
present in the env coding region that folds into a complex secondary structure similar 
to TAR. Rev interacts with cellular transport proteins and mediates nuclear export of 
RRE-containing singly-spliced and unspliced transcripts (Pollard & Malim 1998).  
1.2.1.2.6.  Late events of the life cycle 
Viral structural components are translated from the viral mRNA in the form 
of three polyproteins: Env, Gag-pol and Gag. These proteins translocate to the cell 
membrane after post-traslational modifications and start to assemble, directed by Gag 
polyprotein. The nucleocapsid portion of Gag contains a RNA-binding domain that 
recognises the packaging signal and ensures specific incorporation of genomic RNA 
into the virions.  In addition, all required viral enzymes, cellular tRNAlys3 primer, 
and certain cellular proteins are also incorporated to the immature core (Göttlinger 
2001).  
Depletion of CD4 from the cell membrane is necessary for viral assembly in 
order to avoid its interaction with newly-synthesised gp120.  This is mediated in part 
by Nef, which accelerates endocytosis and degradation of CD4 and MHC (Malim & 
Emerman 2008).  Env also contributes in this process by trapping CD4 bound to 
gp160 in the endoplasmic reticulum, where Vpu induces its degradation (Schubert et 
al. 1996).  Nef has also been involved in depletion of MHC-I from the cell surface. It 
also interacts with several transduction pathways, all of which contributes to HIV-1 
virulence (Quaranta et al. 2009). 
Budding and release of newly formed virions is also mediated by Gag. For 
this process, the virus uses a cellular pathway involved in the sorting of ubiquitinated 
receptors  in  transit  to  lysosomal  degradation  called  endosomal  sorting  complex 
required for transport (ESCRT).  The p6 segment of Gag recruits proteins from the 
ESCRT-III with intrinsic membrane remodelling properties necessary for budding 
from  the  cell  (Martin-Serrano  2007).  Release  of  the  viral  particle  can  also  be 
inhibited by cellular proteins called tetherins; it has been recently demonstrated that 
Vpu counteracts the effects of tetherins, favouring release of the virions (Neil et al. 
2008).       31 
Budding  virions  from  the  cell  are  immature  and  non-infectious.  The  HIV 
viral protease cleaves Gag and Gag-pol polyproteins, inducing morphologic changes 
that result in mature, infectious virions (Sierra et al. 2005).  
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1.3.  Lentivirus attenuation and vector design 
For  the  development  of  HIV-1-based  LVs,  the  HIV  genome  has  been 
modified to abrogate its pathogenic and replication capacity while retaining its ability 
to transfer and integrate in the host genome.  
Firstly,  the  HIV-1  trans-acting  elements  (the  sequences  that  encode  for 
enzymatic,  structural,  accessory  and  envelope  proteins)  are  segregated  from  cis 
elements  (the  non-coding  sequences  required  for  vector  RNA  synthesis,  reverse 
transcription, integration and packaging) (Naldini et al. 1996). These are provided in 
separate expression plasmids that are transiently co-transfected in a packaging cell 
line where the viral particle is assembled. In this way, the possibility of generating 
replication  competent  lentivectors  (RCLs)  is  minimised,  since  at  least  two 
recombination events between the separated viral elements would be required.  
Secondly, dispensable viral genes are removed, especially those contributing 
to HIV-1 pathogenesis. Elimination of Vpr, Vif, Vpu, Nef and Tat leads to fully-
efficient transducing particles, while reinforcing the safety of LVs (Dull et al. 1998; 
Zufferey et al. 1997).  
Thirdly, many of the HIV transcriptional elements in the LTR are eliminated 
to generate self-inactivating (SIN) vectors. This is attained by a deletion of part of 
the U3 region in the 3’ LTR, which serves as a template and is transferred to the 5’ 
LTR  of  the  proviral  DNA  during  reverse  transcription.  The  use  of  SIN  vectors 
reduces  even  more  the  possibility  of  RCL  generation,  hampers  the  likelihood  of 
recombination  with  wild  type  HIV-1  in  the  host  and  avoids  transcriptional 
interference with promoters controlling transgene expression in the transfer vector 
(Zufferey et al. 1998). 
Based on these approaches, the current production of LVs is carried out by 
co-transfection of packaging cells with three (or four, in the latest generation of LVs) 
different expression systems:  envelope, packaging and transfer vectors (Fig. 1.3).       34 
1.3.1. Packaging vector 
  This  vector  encodes  the  enzymatic,  structural  and  accessory  proteins 
necessary to assemble the viral particle. Its components have been modified in the 
past decade to improve its biosafety (Fig. 1.3A-C). 
  ‘First generation’ packaging constructs consist of the human cytomegalovirus 
(CMV) immediate early promoter, driving the expression of all the viral proteins 
required in trans, except the viral envelope and Vpu (Fig. 1.3A). The packaging 
signal (￿) and adjacent sequences have been eliminated in the 5’ end and the 3’ LTR 
was substituted by a polyadenilation signal (Naldini et al. 1996).  Deletion of all the 
accessory genes and preservation of tat and rev led to a safer ‘second generation’ 
packaging vector (Fig. 1.3B) (Zufferey et al. 1997). Further modifications included 
deletion of tat and separation of gag/pol and rev in two different cassettes (Fig. 1.3C) 
(Dull et al. 1998).  For the production of this ‘third generation’ vectors, a fourth 
plasmid  (encoding  rev)  is  required.  This  curtails  even  more  the  risk  of  RCL 
generation, which would then require three recombination events. Furthermore, using 
a  vector  containing  a  synthetic  gag-pol  with  a  codon-optimised  sequence,  gene 
expression can be achieved independently of Rev (Wagner et al. 2000).    
1.3.2. Envelope vector 
  Lentiviruses are enveloped viruses that can be pseudotyped with a variety of 
glycoproteins derived from other enveloped viruses encoded in trans in a separate 
vector. Pseudotyping allows the explotation of the natural tropism of the envelope 
and restricts transduction to specific cells or tissues.  It also prevents the effects of 
neutralising  antibodies  against  viral  envelopes  present  in  the  host  and  facilitates 
vector production and purification (Cockrell & Kafri 2007; Cronin et al. 2005). 
Vesicular  stomatitis  virus  glycoprotein  (VSV-G)  is  the  most  commonly 
employed  envelope  protein  to  pseudotype  LVs  (Fig.  1.3D).    VSV-G  enables 
transduction  of  a  wide  range  of  cell  types.  The  mechanism  of  cell  entry  is  not 
completely clear. It involves fusion to the cell membrane, although no receptor has 
been  identified.  Clathrin-mediated  endocytosis  has  also  been  recently  described       35 
(Cureton et al. 2009). In addition, VSV-G stabilises the viral particle and resists 
concentration by ultracentrifugation without shedding. However,  complement and 
antibody-mediated immune responses against VSV-G can counteract transduction by 
the pseudotyped particles (DePolo et al. 2000). 
There is an ever-growing list of glycoproteins that have been successfully 
used  for  pseudotyping  of  lentivectors.  Examples  are  those  from  Retroviridae, 
Rhabdoviridae,  Arenaviridae,  Flaviviridae,  Paramyxoviridae,  Baculoviridae,  and 
Filoviridae  families  (Bouard  et  al.  2009).  Although  each  of  these  glycoproteins 
preferentially interacts with specific cell types, finding a natural envelope for DC-
specific targeting has been unsuccessful. Therefore, envelopes have been engineered 
in several ways to re-direct their tropism towards specific cell types.  
One way of doing this is by genetically modifying the envelope glycoproteins 
with ligands that bind to receptors present in the target cells. However, ligand-fused 
glycoproteins often result in poor infectivity due to the inability of the retargeted 
envelope to induce membrane fusion and to the sequestration of the viral particles by 
cell surface molecules (Frecha et al. 2008).   
Another  alternative  is  the  modification  of  existing  envelopes  to  re-direct 
receptor attachment without affecting membrane fusion.  Yang et al. (2008) showed 
that by introducing a mutation to the envelope of Sindbis virus, its affinity to an 
ubiquitous receptor (heparan sulphate) was ablated while preserving its capacity of 
binding  to  DC-SIGN,  a  lectin-type  receptor  present  on  some  DC  subsets.  LVs 
encoding ovalbumin (OVA) pseudotyped with this modified envelope specifically 
transduced  DCs  in  vivo  and  induced  immune  responses  against  OVA-expressing 
tumors.  
Conjugation of the viral envelope with single-chain antibodies (scFv) specific 
for surface proteins present on the target cells has also been used for this purpose. 
For example, specific targeting of DCs has been achieved with antibodies directed 
against  C-type  lectins,  such  as  DEC-205  (Bonifaz  et  al.  2002)  and  DC-SIGN 
(Dzionek et al. 2001). Display of scFv in the context of measles virus envelope 
glycoproteins  seems  to  be  a  promising  approach  since  measles  virus  enters  cells 
through direct fusion with cell membranes. In this system, the natural tropism of 
measles  virus  is  modified  by  introducing  a  mutation  in  the  contact  residues  of       36 
haemagluttinin and fusing a scFv to its ectodomain (Nakamura et al. 2005). The 
resulting virus infects cells that express the cognate cell-surface antigen. Funke et al. 
(2008) demonstrated target versus non-target cell discrimination in vitro by using 
LVs pseudotyped with re-targeted measles virus envelope and different scFv.  
1.3.3. Expression vector 
  This component consists of a full-length vector RNA molecule that contains 
the cis acting elements required for efficient packaging, reverse transcription, nuclear 
import  and  integration,  as  well  as  the  expression  cassette  of  interest  (internal 
promoter  and  transgene  sequence).  Improvement  of  transgene  expression  and 
transduction efficiency has been attained by the incorporation of two cis elements: 
the cPPT and the woodchuck hepatitis virus post-transcriptional element (WPRE) 
(Fig. 1.3E).   
The function of cPPT was described before. When included in the LVs, it 
enhances transduction efficiency  by 2-10 fold in dividing and non dividing cells 
(Zennou  et  al.  2001;  Firat  et  al.  2002).  WPRE  also  increases  expression  of  the 
transgene  (Zufferey  et  al.  1999).  It  has  been  proposed  that  WPRE  could  incite 
oncogenic activity because it contains enhancer/promoter elements and encodes part 
of  the  woodchuck  hepatitis  virus  X  protein,  associated  with  hepatic  oncogenesis 
(Kingsman et al. 2005).  However, recent data on insertional mutagenesis do not 
support this and the risk has been further reduced by abrogating the X protein open 
reading frame of  WPRE (Modlich et al. 2009; Zanta-Boussif et al. 2009). 
The gene of interest driven by a heterologous promoter is also included in the 
expression  vector.  Tissue-specific  promoters  have  been  used  to  target  gene 
expression  to  specific  cell  types.  For  example,  LVs  with  B7-DC  and  CCL17 
promoters  result  in  transgene  expression  in  murine  bone  marrow-derived  DCs 
(BMDCs) but not in macrophages (Gorski et al. 2003). Gene expression has also 
been specifically attained in some DC subpopulations using the dectin-2 promoter. A 
LV encoding an antigen  gene driven by the dectin-2 promoter resulted in an immune 
response  comparable  to  that  obtained  with  LVs  containing  a  strong  constitutive 
promoter (Lopes et al. 2008).   
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1.4.  Lentiviral vectors for immunotherapy 
  The first evidence for the potential use of LVs in immunotherapy came from 
the observation that they transduce DCs. Murine BMDCs as well as human DCs 
derived from monocytes or CD34
+ haemopoietic precursors can be transduced in 
vitro  with  VSV-G-pseudotyped  LVs  with  efficiencies  ranging  from  35  to  90% 
(Chinnasamy et al. 2000; Cui et al. 2002; Esslinger et al. 2002; Oki et al. 2001; 
Rouas et al. 2002; Schroers et al. 2000; Unutmaz et al. 1999; VandenDriessche et al. 
2002).  LV-transduced DCs show no obvious signs of cellular toxicity and keep their 
ability  to  present  allogeneic  antigens,  respond  to  maturation  stimuli  such  as 
lipopolysaccharide  (LPS)  or  CpG,  and  secrete  stimulatory  cytokines  (e.g., 
interleukin-12) (He et al. 2005).  
  The second relevant aspect is that the transgene product is also processed and 
presented in the context of the major histocompatibility complex (MHC). This has 
been demonstrated with model antigens such ovalbumin (OVA), TAAs (Melan-A, 
tyrosinase related protein, NY-ESO) and antigens from various infectious agents, 
including  flu  or  lymphocytic  choriomeningitis  virus  (LCMV)  (Dyall  et  al.  2001; 
Lopes et al. 2006; Metharom et al. 2001; Palmowski et al. 2004; Zarei et al. 2004).  
DCs  transduced  with  LVs  encoding  these  antigens  induced  proliferation  and 
activation of both class I or class II-restricted T cell lines or transgenic lymphocytes 
bearing the cognate T cell receptor. 
  The results of in vitro experiments are reflected in vivo following injection of 
LV-transduced  DCs  in  mice.  Esslinger  et  al.  (2002)  observed  proliferation  and 
activation of antigen-specific CD8
+ T cells in mice after injecting DCs transduced 
with a LV encoding HLA-Cw3, a model antigen. The response was better than that 
observed using an adenoviral vector. In a similar model, He et al. (He et al. 2005), 
showed that the in vivo lytic T cell response against OVA was stronger and lasted 
longer  with  LV-transduced  DCs  as  compared  with  peptide-pulsed  cells.  Indeed, 
immunisation with LV-transduced DCs protected mice from a challenge with OVA-
expressing tumoral cells and inhibited growth of established tumours.       39 
  DC transduction after direct administration of LVs has been demonstrated in 
vivo both in the spleen and in lymph nodes after systemic or subcutaneous injections, 
respectively   (Esslinger et al. 2003; Palmowski et al. 2004; VandenDriessche et al. 
2002).  Following these studies, the effectiveness of direct administration of LVs has 
been shown by several research groups (Table 1.2). Although there has been great 
interest on tumoral models, some have also investigated the potential use of LVs 
against infectious diseases.   
                                                          
Table 1.2.  Overview of studies involving direct in vivo administration of LVs for immunisation. 
 
Antigen  Dose & route of 
administration  Boosting  Characterisation of immune 
response  Endpoint analysis  Reference 
Cw3 
Melan-A 
2 x 10
7 EFU sc 
footpad or base of 
tail 
No  CD8
+ T cell response, 
CD4
+ T cell-dependent in the case 
of Melan-A but not Cw3 
Elimination of targets in in vivo cytotoxicity assay 
Poor secondary response to challenge with same LV (anti-
vector immunity?) 
Esslinger et al. 
2003 
NY-ESO-1  5 x 10
7 IU iv tail 
vein 
NY-ESO-1-VV, 
day 8 
CD8
+ T cell response 
 
Elimination of targets in in vivo cytotoxicity assay; boosting 
improved response 
 
Palmowski et al. 
2004 
Trp2/hsp70 
 
 
Neu/hsp70 
1.6 x 10
7 PFU sc 
footpad 
No  CD8
+ T cell  response 
 
Decreased growth of small established B16 or G-26 tumours  
 
Decreased growth  of established spontaneous mammary 
gland tumours in BALB/c-Neu transgenic mice 
Kim et al. 2005 
Full-length HIV-1 
Rev/Env 
Codon-optimized 
HIV-1 gp120 
1 x 10
7 RT units 
im 
No  CD8
+ T cell  response 
Humoral response 
In vitro cytotoxicity assay  Buffa et al. 
2006 
Melan-A  4 x 10
6 EFU sc 
base of tail 
No  CD8
+ T cell  response 
 
Elimination of targets in ex vivo and in vivo cytotoxicity 
assays 
Effective secondary response to challenge with peptide 
Chapatte et al. 
2006 
OVA  1 x 10
6- 1 x 10
7 iu 
sc 
OVA-LV, day 150  CD8
+ and CD4
+ (TH1) T cell 
response; CTL response partially 
dependent on CD4
+ T cells 
Elimination of targets in in vivo cytotoxicity assay 
Decreased growth of established EG.7 tumours 
Dullaers et al. 
2006 
E-glycoprotein West 
Nile virus 
500 ng p24 ip  No  Humoral response (primary and 
memory) 
Protection against challenge with West Nile virus   Iglesias et al. 
2006 
OVA  1 x 10
6 sc  No  CD8
+ T cell response   Elimination of targets in in vivo cytotoxicity assay 
Protection from B16-OVA tumour challenge 
He et al. 2006 
OVA  1 x 10
7 iu iv tail 
vein 
OVA –VV, week 
3 
CD8
+ and CD4
+ T cell response 
Humoral response 
Complete protection against EG.7 tumour challenge  Rowe et al. 
2006 
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a Immunisations with non-integrating LVs.  
b Study performed with macaques; the rest were done in mice. 
Antigen  Dose & route of 
administration  Boosting  Characterisation of immune 
response  Endpoint analysis  Reference 
HIV-1-derived 
restricted 
polyepitopes 
0.2-1 x 10
8 TU ip  No  CD8
+ and CD4
+ T cell response; 
CTL response partially dependent 
on CD4
+ T cell priming 
Elimination of targets in in vivo cytotoxicity assay 
 
Iglesias et al. 
2007 
Trp2  2 ￿g p24 iv  Trp2-LV, day 7  CD8
+ T cell response 
 
Increase in survival following tumour challenge with B16 
cells using CMV promoter was used, but not with MHC-II 
specific promoter 
Kimura et al. 
2007 
Codon-optimized 
HIV-1 gp120
a 
1.3 x 10
7 RT units 
im 
No  CD8
+ T cell reponse 
Humoral response 
In vitro cytotoxicity assay  Negri et al. 
2007 
NY-ESO-1  4 x 10
6 TU sc base 
of tail 
No  CD8
+ and CD4
+ T cell response 
Humoral response 
No functional assays  Garcia Casado 
et al. 2008 
NY-ESO-1  0.001-1 x 10
8 iu sc 
base of tail or  
1 x 10
8 iu iv 
NY-ESO-1-VV, 
week 3 
CD8
+ and CD4
+ T cell response 
 
No functional assays  Lopes et al. 
2008 
Mutated Trp-1  2.5 x 10
7 TU sc 
footpad 
No  CD8
+ T cell response 
 
Elimination of targets in in vivo cytotoxicity assay 
Protection against challenge with B16 cells 
Elimination of early-stage and inhibition of growth in 
established B16 tumours 
Liu et al. 2009 
CEA  0.15 x 10
6 TU sc in 
footpad 
CEA-LV, weekly 
x 3 doses 
CD8
+ and CD4
+ (TH1 and TH2) T 
cell response 
Humoral reponse 
 
Regression of CEA-expressing tumours; poor long-term 
protection (loss of cellular response and tumour regrowth 
after day 36) 
Loisel-Meyer et 
al. 2009 
SIVmac239 gag non-
secreted protein 
b 
0.25-1 x 10
8 TU sc  Gag-LV with a 
different 
envelope, day 79 
CD8
+ and CD4
+ T cell response 
Humoral response 
 
Protection against intrarrectal challenge with SIVmac251  Beignon et al. 
2009 
OVA
a 
 
Secreted hepatitis B 
virus surface antigen 
150 ng RT sc 
 
1 x 10
7 iu im 
No 
 
No 
CD8
+ T cell response 
 
CD8
+ T cell and humoral 
responses 
Partial regression and increased survival of mice bearing 
EG.7 tumours. 
 
 
Karwacz et al. 
2009 
4
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1.4.1. Interaction of LVs with DCs 
The  regulation  of  the  cellular  immune  response  by  DCs  depends  on  the 
delivery  of  different  ‘signals’  to  receptors  present  in  lymphocytes  (Janeway  & 
Bottomly 1994). ‘Signal 1’ is antigen-specific and depends on the recognition of the 
MHC/peptide complex by cognate T cell receptors.  Activation and expansion of T 
cells also requires a co-stimulatory ‘signal 2’,  which results from the  balance of 
several positive and negative signals delivered to particular receptors in the T cells. 
Classical co-stimulatory molecules in DCs are CD80 (B7.1) and CD86 (B7.2), which  
interact with CD28 in T cells and induce their clonal expansion, cytokine secretion 
and effector functions (Seliger et al. 2008). DCs also provide a third signal (‘signal 
3’) through cytokines that exert multiple functions, such as regulation of the CTL 
activity of CD8
+ T cells, polarisation of the CD4
+ T cell response and generation of 
regulatory T cells, among others  (Curtsinger  et al. 1999; Curtsinger  et al. 2003; 
Kali￿ski  et  al.  1999).    Thus,  a  vaccine  should  provide  both  the  antigen  to  be 
presented and th components necessary to induce DC maturation in order to deliver 
adequate signals 2 and 3.  There is evidence that immunisation with LVs provides 
these signals. 
1.4.1.1.  Processing of LV-encoded antigens: Delivery of ‘signal 1’ 
  Antigen  processing  and  presentation  has  classically  been  divided  in  two 
different  pathways.  Endogenous  antigens  are  processed  through  an  intracellular 
pathway  that  results  in  presentation  to  CD8
+  T  cells  in  the  context  of  MHC-I.  
Exogenous antigens follow an endocytic pathway and are presented to CD4
+ T cells 
in the context of MHC-II. However, cross-talk between the two pathways can take 
place.  Exogenous  peptides  can  be  presented  by  MHC-I  (cross-presentation)  and 
endogenous antigens by MHC-II (‘biosynthetic’ pathway). This cross-presentation is 
particularly  important  in  the  context  of  immunity  against  infectious  diseases  and 
cancer (Basta & Alatery 2007).      43 
  Processing of the antigen genes delivered by LVs reach the MHC-I following 
the  same  pathway  as  ‘endogenous’  products,  such  as  cellular  or  viral  proteins 
produced  in  infected  cells.  A  proportion  of  these  newly  synthesised  proteins  are 
degraded by the proteasome and immunoproteasome. The resulting peptides can then 
be translocated to the lumen of the endoplasmic reticulum (ER) by the transporter 
associated  with  antigen  processing  (TAP)  and  by  other  TAP-independent 
mechanisms (Yewdell et al. 1998).  As expected, TAP plays an important role in the 
processing of LV-encoded antigens, since no class I antigen presentation is observed 
in TAP-deficient cells transduced with LVs (Zarei et al. 2002).   
  In the ER, the peptides are loaded onto MHC-I heterodimers through peptide-
loading complexes, a mechanism that is highly regulated by a variety of chaperones 
and other proteins. Once class I molecules are loaded with stably-bound peptides, 
they are released from the peptide-loading complex and shuttled to the cell surface 
via the Golgi complex for antigen presentation (Buckwalter & Albert 2009; Van 
Kaer 2002; Vyas et al. 2008). 
On  the  other  hand,  ‘exogenous’  antigens  are  internalised  in  APCs  by 
phagocytosis, endocytosis or both,  and then enzymatically  degraded in endocytic 
compartments. Here they encounter the MHC-II molecules.  After its synthesis in the 
ER, the MHC-II is associated with a pre-assembled trimer called invariant chain (Ii) 
that blocks the peptide-binding cleft and prevents binding of endogenous peptides in 
the ER, among other functions.  The Ii is degraded by the endosomal hydrolases, 
except for a short fragment—the class II-associated invariant chain peptide (CLIP)—
which  remains  bound  to  the  peptide-binding  cleft.    CLIP  is  then  exchanged  for 
processed peptides in the endosomal compartments, a mechanism that is regulated by 
other ‘non classical’ MHC-II molecules. The stable MHC-II/peptide complexes are 
finally transported to the plasma membrane for antigen presentation (Vyas et al. 
2008; Jensen  2007).  Class  II  antigen  presentation  is  important  in  vaccination,  as 
CD4
+ T cells play a critical role in the immune response.  
Proteins  encoded  by  LVs  can  reach  MHC-II  through  several  pathways. 
Secreted proteins can be taken up directly by DCs or neighbouring cells and enter the 
endocytic pathway, although this mechanism is probably inefficient.  Membrane-
bound proteins enter the recycling pathway, which leads to endosomal localisation     44 
and processing. Proteins can also be traslocated to the ER and then passed to the 
Golgi, where they can go directly into endosome and be processed. If the protein 
does not enter the ER  and remains in the cytoplasm, there is very little class  II 
processing.  However,  these  proteins  can  occasionally  reach  this  pathway  during 
autophagy  by  fusion  of  autophagosomes  with  the  MHC-II-loading  compartments 
(Paludan et al. 2005).  
Several molecular approaches have also been employed to improve class II 
processing of intracellular peptides encoded by LVs or other vectors. One strategy is 
engineering  chimeric  genes  that  encode  the  antigen  plus  specific  proteins  of  the 
endocytic route, such as lysosomal-associated membrane protein 1 (LAMP-1) or the 
invariant chain (Gregers et al. 2003; Sanderson et al. 1995; Wu et al. 1995).  This 
method enhances MHC-II  presentation  and increases the efficacy of the immune 
response to certain antigens (Rowe et al. 2006). 
Exogenous antigens can also be cross-presented by MHC-I by some APCs, in 
particular  by  DCs.    Although  the  exact  cellular  mechanism  is  not  completely 
understood, it involves direct transport of the antigen from the phagosome or early 
endosomes  to  the  cytoplasm  for  proteasome  processing,  or  direct  fusion  of 
phagosomes with the ER (Jensen 2007).  This mechanism seems to be important for 
the presentation of antigens derived from apoptotic cells or from transduced non- 
professional APCs following vaccination with  DNA or viral vectors (Pang et al. 
2009; Schulz et al. 2005). 
1.4.1.2.  DC maturation and delivery of signals ‘2’ and ‘3’ by  LVs 
  Antigen presentation in the context of appropriate co-stimulation (‘signal 2’) 
and  cytokine  stimulus  (‘signal  3’)  are  critical  for  the  generation  of  an  adequate 
immune responses. This is directly related to the maturation state of the DCs.  It is 
widely accepted that immature DCs, which present antigen but do not deliver co-
stimulatory signals and stimulatory cytokines, induce T cell tolerance. Instead, the 
presence of co-stimulation and activating cytokines results in potent induction of 
immunity (Jonuleit et al. 2001; Probst et al. 2003; Reis e Sousa 2006).  This has been 
confirmed  in  multiple  experiments  in  which  antigen  presentation  by  adoptively     45 
transferred immature DCs or antigen delivery to DCs in the steady state result in T 
cell  anergy  and/or  induction  of  regulatory  T  cells  (Treg)    (Bonifaz  et  al.  2002;  
Dhodapkar et al. 2001; Dhodapkar  & Steinman 2002; Hawiger  et al. 2001).   In 
contrast,  ex  vivo  activated  DCs  or  concomitant  in  vivo  administration  of  DC 
activators and antigen induce potent immune responses (Banchereau  & Steinman 
1998; Dhodapkar et al. 1999; Probst et al. 2003). 
1.4.1.2.1.  Overview on dendritic cell activation 
  Maturation of DCs is regulated by a variety of signals, such as microbial 
patterns, ‘danger’ signals and inflammatory cytokines. They are sensed by pattern 
recognition  receptors  (PRRs)  that  include  Toll-like  (TLRs),  nucleotide-binding 
oligomerisation domain (Nod)-like, retinoic acid induced gene (RIG)-I-like and C-
type lectin receptors (Fritz et al. 2006; H. Kato et al. 2005; Geijtenbeek & Gringhuis 
2009).  These  sensors  play  an  important  role  in  linking  the  innate  and  adaptive 
immune  responses.    Sensing  the  ‘danger’  signals  results  a  series  of  phenotypic 
changes in DCs, which switch from an antigen-capturing to an antigen-presenting 
and T cell-stimulating cell.  During the process of DC maturation, the cells migrate 
to  secondary  lymphoid  organs,  assemble  peptide-MHC  complexes  and  produce 
cytokines (Reis e Sousa 2006). 
  Among the PRRs, the TLRs have been extensively studied in DCs. These are 
a  family  of  receptors  present  on  the  cellular  and  endosomal  membranes  that 
recognise  several  pathogen-associated  molecular  patterns  (PAMPs).  They  are 
differentially expressed among DC subsets. For example, CD8
+ DCs express TLR3, 
but not TLR5 or TLR7, while pDCs express mainly TLR7 (in mice and humans) and 
TLR9 (in mice), but very low level of TLR3 (Reis e Sousa 2004). Thus, different 
types of ligands can activate different DC subtypes.  
The role of TLRs in the activation of adaptive immunity is well established 
(Iwasaki & Medzhitov 2004). TLR signalling controls antigen uptake, processing 
and loading onto MHC molecules (Blander & Medzhitov 2006; Cella et al. 1997). It 
also downregulates chemokine receptor (CCR)-5 and upregulates CCR-7, facilitating 
DC migration to lymph nodes (Means et al. 2003).  In many cases, TLR stimulation     46 
results  in  a  T  helper  1  (TH1)-polarised  CD4
+  T  cell  response  characterised  by 
secretion of inflammatory cytokines like interleukin (IL)-1, IL-6, tumour necrosis 
factor (TNF)-￿ and IL-12 (van Duin et al. 2006). Importantly, it has been shown that 
stimulation  of  TLRs  is  necessary  to  break  tolerance  to  self-  and  TAAs  by 
counteracting Treg (Lang et al. 2005; Yang et al. 2004). 
One of the consequences of TLR stimulation is the upregulation of the co-
stimulatory molecules CD80 (B7.1), CD86 (B7.2), CD40 and CD70 on DCs (Iwasaki 
& Medzhitov 2004). CD80 and CD86 belong to the ‘B7 family’, which also includes 
the co-inhibitory molecule programmed death ligand (PDL)-1. These molecules bind 
receptors from the CD28 family on T lymphocytes. Engagement of CD28 by CD80 
and CD86 results in cytokine secretion and inhibition of apoptosis, consequently 
enhancing the immune response. Interestingly, these molecules also have inhibitory 
functions.  Either engagement of PDL-1 to its receptor, PD-1, or of CD80 and CD86 
to another receptor of the CD28 family, cytotoxic T lymphocyte antigen (CTLA)-4, 
attenuate the T cell response and prevent T cell hyperactivation (Seliger et al. 2008). 
CD40  is  a  receptor  of  the  TNF  receptor  superfamily.  Its  ligand,  CD40L 
(CD154), can exist in a soluble form or on the cell membrane of activated T cells, B 
cells, platelets, monocytic cells, natural killer (NK) cells, mast cells and basophils. 
Upon engagement, CD40 induces cytokine production, expression of co-stimulatory 
molecules  and  antigen  cross-presentation  by  DCs  (Elgueta  et  al.  2009).  CD40 
signalling also promotes DC survival and is involved in the protection of APCs from 
CTL-mediated  elimination  (Mueller  et  al.  2006).    The  cellular  response  against 
specific antigens can be enhanced by induction of CD40L expression in DCs using 
mRNA electroporation or viral vectors (Bonehill et al. 2009; Koya et al. 2003; Liu et 
al. 2008; Thacker et al. 2009).   
CD70 binds to its receptor, CD27, expressed on the surface of CD8
+ and 
CD4
+ T cells, NK cells and activated B cells. This receptor is also member of the 
TNF  receptor  superfamily  and  delivers  important  signals  for  cell  survival  and 
differentiation of T cells (Borst et al. 2005).  CD70 expression in DCs contributes to 
T cell priming (Schildknecht et al. 2007) and can break CD8
+ T cell tolerance (Keller 
et al. 2008). For this reason, it has been used in some vaccination strategies (Keller et 
al. 2009; Bonehill et al. 2008).      47 
1.4.1.2.2.  Dendritic cell activation by LVs 
  Based on the above evidence, it is clear that to elicit an immune response LVs 
should not only deliver the antigen but also activate the DCs. The latter may be 
achieved by (1) components of the viral particle itself, (2) components of the viral 
preparation other than the viral particle and (3) delivery of transgenes involved in 
activation pathways. 
1.4.1.2.2.1.  DC activation by LV particles 
  Although LVs do not express viral proteins, some of the vector components 
could  potentially  stimulate  the  innate  immune  system.    Single  stranded  RNA 
contained in the viral core is a ligand of TLR7. Double stranded DNA, generated 
after reverse transcription of the viral genome, can engage TLR9.  
Some evidence supports LV-mediated activation of DCs. HIV-1, the parental 
virus of most LVs, induces pDC maturation and type I IFN secretion in vitro through 
TLR7 stimulation (Beignon et al. 2005; Fonteneau et al. 2004).  Type I IFN induces 
autocrine maturation of pDCs and also of ‘bystander’ myeloid DCs. This has also 
been  shown  in  vivo,  where  administration  of  LVs  induced  a  rapid  and  transient 
secretion of type I IFN initiated by pDCs; when the ability to respond to IFN-￿/￿ was 
absent, the clearance of transduced cells was abolished (Brown et al. 2007). These 
studies contrast with others in which transduction of pDCs by LVs did not affect 
their activation phenotype (Veron et al. 2009). 
The effects of LVs on conventional DCs (cDCs) are less clear.  In several 
studies,  no  changes  in  the  immunophenotype  of  cDCs  were  observed  upon 
transduction with LVs or infection with HIV-1 (Beignon et al. 2005; Schroers et al. 
2000; Gruber et al. 2000).  In contrast, Harman et al. (Harman et al. 2006) reported 
that infection of monocyte-derived DCs (MoDCs) with live or inactivated HIV-1 
resulted in a partially mature phenotype.  Breckpot et al (Breckpot et al. 2007) also 
reported upregulation of co-stimulatory (CD25, CD80, CD83) and HLA molecules, 
as  well  as  enhanced  secretion  of  pro-inflammatory  cytokines  (IL-6,  TNF-￿)  and 
allostimulatory  capacity  on  MoDCs  transduced  with  LVs.  Engagement  of  TLR2,     48 
TLR3 and TLR8 seem to mediate this process. However, in this study, DC activation 
was only observed at high multiplicity of infection.  
More  recently,  it  has  been  shown  that  LVs  induce  activation  of  murine 
myeloid  DCs  through  a  TLR-3/TLR-7-dependent  mechanism  (Breckpot  et  al., 
submitted).  These discrepancies among studies could be explained by differences in 
experimental designs, including the origin of the DCs, the way the virus is produced 
and concentrated and the amount of virus used. 
1.4.1.2.2.2.  DC activation by other components of the viral preparation 
By-products  present  in  the  vector  preparation  can  affect  the 
immunostimulatory properties of LVs.   Viral preparations of VSV-G-pseudotyped 
LVs  contain  tubulo-vesicular  structures  that  contain  nucleic  acids,  that  stimulate 
TLR9, induce type I IFN production by pDCs and elicit T and B cell responses to co-
administered proteins (Pichlmair et al. 2007).  The presence of residual foetal calf 
serum (FCS) in concentrated viral pellets can also be immunogenic. Bao et al. (2009) 
showed generation of CD4
+ T cells specific for epitopes in FCS components which 
could potentially affect the CD4
+ T cell help in the immune response.  
1.4.1.2.2.3.  Delivery of transgenes involved in activation pathways 
  DC  function  can  be  modulated  by  delivering  genes  involved  in  DC 
differentiation  and  maturation  pathways.    This  can  be  achieved  by  expressing 
downstream effectors or intermediate molecules that stimulate or inhibit different 
signalling cascades. The most common targets are TLR signalling, mitogen-activated 
protein kinase and (MAPK) and nuclear factor ￿B (NF-￿B) pathways.  
  TLR signalling can be emulated in the absence of ligands by expression of 
adaptor  molecules  associated  with  this  pathway.  For  example,  transduction  of 
BMDCs with LVs encoding Myd88 or TRIF-1 results in secretion of IL-6 and IL-12 
or IFN-￿ production, respectively, and enhanced cytotoxicity (Akazawa et al. 2007). 
  Activation of the NF-￿B pathway has been achieved using LVs encoding the 
Kaposi  sarcoma-associated  herpes  virus  (KSHV)  FLICE-like  inhibitory  protein 
(vFLIP),  which  activates  the  classical  and  alternative  NF-￿B  pathways.  Co-    49 
expression of this molecule with OVA resulted in DC activation, enhanced CD8
+ T 
cell  responses,  improved  tumour-free  survival  in  a  tumour  therapy  model  and 
reduction of parasite load after a challenge with OVA-leishmania (Rowe et al. 2009).  
NF-￿B activation has also been attained by inhibiting A20, which inhibits NF-￿B by 
deactivation of some of the adaptor molecules that take part in the signalling of 
TLRs, TNF and IL-1 receptors. Transduction with a LV encoding a short hairpin 
RNA (shRNA) against A20 resulted in upregulation of co-stimulatory molecules and 
pro-inflammatory cytokines in DCs, enhanced CD8
+ T cell response and inhibition 
of Treg (Breckpot et al. 2009; Song et al. 2008). 
  The  MAPK  pathway  has  also  been  manipulated  by  using  constitutively 
activated or dominant negative mutants.  Escors et al. (2008) showed that activation 
of p38 and JNK1 with constitutively active mutants of MKK6 and the fusion protein 
MKK7-JNK1,  respectively,  resulted  in  upregulation  of  co-stimulatory  molecules 
(CD40 and CD80) in DCs, although no increase in secretion of pro-inflammatory 
cytokines.  Co-expression of these molecules with OVA or other human relevant 
antigens resulted in a better CD8
+ T cell response and improved survival in murine 
tumoral models.  In contrast, activation of ERK1/2 pathway with an active mutant of 
MEK1, and activation of IRF3 resulted in inhibition of the immune response and 
increase in the number of CD4
+ CD25
+ FoxP3
+ T cells. These results have been 
confirmed in the context of immunisation with non-integrating lentivectors (Karwacz 
et al. 2009). 
1.4.2. Clinical application of LVs 
Until  now,  LVs  have  not  been  employed  clinically  as  vaccine  vectors. 
However, they have been used in gene therapy clinical trials, showing encouraging 
results regarding their safety and efficacy. 
In the first reported clinical trial, LVs were used to express an antisense gene 
against the HIV envelope in autologous CD4
+ T cells that were then transferred to 
infected patients. Sustained gene transfer and no evidence of insertional mutagenesis 
were shown in a follow up of 21-36 months. The data also showed self-limiting 
mobilisation of the vector and improvement of the immune function in four out of     50 
five treated subjects (Levine et al. 2006).  LVs are also being used in other gene 
therapy  clinical  trials  for  the  treatment  of  X-linked  adrenoleukodystrophy,  ￿-
thalassemia, sickle-cell anaemia and Parkinson’s disease (D' Costa et al. 2009).  
 
1.5.  Justification and aims of the PhD project 
  LVs  have  several  advantages  that  make  of  them  promising  tools  for 
immunotherapy. These include (1) efficient transduction and stable gene expression 
in  professional  APCs,  particularly  in  DCs,  (2)  low  toxicity,  (3)  relatively  high 
packaging capacity, (4) low antivector immunity and (5) the possibility of regulating 
the  immune  response  by  the  viral  particle  itself  or  by  co-expression  of 
immunomodulators.  Their  effectiveness  has  been  demonstrated  in  multiple  pre-
clinical models in mice and, more recently, in macaques (Table 1.2). Furthermore, 
reports of early gene therapy clinical trials have documented their safety. Although 
they have not yet been employed for immunotherapy, all this evidence supports the 
possibility of their application, possibly for the treatment of serious conditions such 
as malignant diseases. 
  Integration  into  the  host  genome  allows  LVs  to  sustain  expression  of  the 
transgene during the lifespan of the target cell and its progeny.  This has been shown 
in different organs and tissues, e.g., liver (Kang et al. 2005a), neurons (Naldini et al. 
1996), retina (Ikeda et al. 2009) and cells of the haemopoietic system (Marangoni et 
al. 2009). Sustained expression is a favourable feature that has been exploited for the 
correction of genetic diseases. However, for genetic immunisation, this property is 
questionable  since  sustained  expression  of  antigen  is  not  absolutely  necessary  to 
elicit  an  efficient  immune  response  and  the  consequences  of  prolonged  antigen 
presentation are not always favourable.  
  Two key unanswered questions in the use of LVs are for how long do DCs 
produce antigen and what are the consequences of sustained transgene expression in 
professional APCs. This thesis will attempt to address these questions. Therefore, the 
main objectives of this PhD are:     51 
 
·  Determine  the  duration  of  antigen  presentation  by  professional  APCs 
following antigen gene delivery by lentiviral vectors. 
 
·  Study the immune consequences of persistent antigen in the long term.  
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CHAPTER 2 
2. MATERIALS AND METHODS 
2.1.  Molecular biology techniques 
2.1.1. Molecular buffers and bacterial media 
The buffers and bacterial media are summarised in table 2.1.  For general 
purposes, plasmid DNA was stocked in solution in EB or TE buffer at 1 µg/µL. 
2.1.2. Restriction digestions and ligations 
All restriction enzymes used were purchased from Promega (Madison, WI) or 
from New England Biolabs (Ipswich, MA).  Digestions of plasmid DNA were done 
for at least one hour in the conditions recommended by the manufacturers for each 
combination of enzymes in a final volume of 10 µL (1 µL DNA, 16 µL water, 0.5 µL 
each enzyme, 2 µL buffer 10X) or 30 µL (10 µL DNA, 15 µL water, 1 µL each 
enzyme, 3 µL buffer 10X).    
  DNA fragments were ligated overnight at ~17º C in presence of T4 DNA 
ligase and its respective buffer (New England Biolabs). Ligations were done in a 
final volume of 10 µL (4 µL of each DNA fragment, 1 µL T4 DNA ligase, 1 µL 
buffer 10X). 
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Table 2.1. Buffers and media for molecular biology 
 
Buffers/media  Composition 
 
1X phosphate-buffered saline (PBS) 
 
137 mM NaCl, 2mM KCl, 10 mM sodium 
hydrogen phosphate (dibasic), 2 mM 
potassium hydrogen phosphate (dibasic), pH 
7.4 
 
Tris-EDTA buffer (TE)  10 mM Tris.Cl, 1mM EDTA, pH 8.0 
 
EB buffer  10 mM Tris.Cl, pH 8.5 
 
1X tris-acetate EDTA buffer (TAE)  40 mM Tris (pH 7.8), 20 mM sodium acetate, 
1 mM EDTA 
 
Luria Bertani agar  LB broth plus bacto-agar 15 g/L 
 
Luria Bertani broth  1% bacto-tryptone, 0.5% bacto-yeast extract, 
10% NaCl, pH 7.0 
 
6X gel loading buffer  0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 30% glycerol in water 
 
Transformation buffer (TFB)-I   30 mM potassium acetate, 100 mM rubidium 
chloride, 10 mM calcium chloride, 50 mM 
magnesium chloride, 15% glycerol, pH 5.5 
with acetic acid 
 
TFB-II  10 mM MOPS, 75 mM calcium chloride, 10 
mM rubidium chloride, 15% glycerol, pH 6.5 
with KOH 
 
 
2.1.3. Agarose gel electrophoresis 
  Electrophoreses were done in 1% agarose (Invitrogen, Carlsbad, CA) gels 
with 5 µg/mL ethidium bromide (Dutscher Scientific, Essex, UK).  A 1-Kb Plus 
DNA ladder (Invitrogen, Carlsbad, CA) was run in parallel to indentify the band 
sizes. 
For DNA purification after electrophoresis, the section of the gel containing 
the desired DNA fragment was cut out and the DNA purified using QIAquick Gel     54 
Extraction  Kit  (Qiagen,  Hilden,  Germany)  according  to  the  manufacturer’s 
instructions. 
2.1.4.  Preparation and transformation of competent bacteria 
  Competent XL1-Blue E. coli were prepared by selection in tetracycline (10 
µg/mL) using the rubidium chloride method (buffers TBF-I and TBF-II) as described 
elsewhere (Bokhoven 2008). Aliquots of 100 µL were kept at -80º C until used. 
For transformation, competent bacteria were thawed on ice and inoculated 
with 1-3 µg of plasmid DNA or 3-5 µL of ligation reaction. After incubation on ice 
for 20 minutes, the bacteria were heat shocked for 2 minutes at 37º C and put back on 
ice for further 2 minutes. Transformed cells were then grown overnight in LB agar 
plates at 37º C.  All clones were selected based on ampicillin resistance (50 µg/mL). 
2.1.5. DNA purification and quantification 
  Single colonies were picked from LB agar plates and grown overnight at 37º 
C in 3 mL (minipreps), 150 mL (midipreps) or 400 mL (maxipreps) of LB broth with 
ampicillin (50 µg/mL).  Plasmid DNA was purified using QiaPrep Spin Miniprep, 
Plasmid  Midi  and  Plasmid  Maxi  kits  (Qiagen)  according  to  manufacturer’s 
instructions.   
  The  concentration  of  DNA  was  determined  using  a  Hitachi  U-1500 
spectrophotometer and the concentration calculated using the following formula:   
 
Concentration (ng/µL) = Absorbance260 nm x Dilution factor x 50 
2.1.6. Polymerase chain reaction (PCR) 
  PCR  reactions  were  done  using  Hotstar  Taq  DNA  polymerase  (Qiagen).  
Table 2.2 summarises the reagents used for one reaction in a volume of 50 µL. 
Reactions were run in a Hybraid thermal cycler, performing 25-30 cycles with the 
parameters shown in Table 2.3.     55 
  Table 2.2. Polymerase chain reactions (for one reaction of 50 ￿L). 
 
Reactive  Stock 
concentration 
Volume 
added 
Final 
concentration 
10X PCR buffer  10X  5.25 ￿L  1X 
dNTPs  2.5 mM  1.5 ￿L  200 µM of each 
dNTP 
Forward primer  1 ￿g/ ￿L  1 ￿L  0.5 µM 
Reverse primer  1 ￿g/ ￿L  1 ￿L  0.5 µM 
Taq polymerase  5 U/µL  0.3 ￿L  2.5 U/100 µL 
reaction 
MgCl2  25 mM  4 ￿L  1.5 mM 
DTT  1 M  0.05 ￿L  1￿M 
DNA  1 ￿g     
Distilled water    Complete 
volume to 50 ￿L   
 
 
 
 
Table 2.3. Thermocycler parameters for PCR (25-30 cycles). 
 
Phase  Time  Temperature 
Initial activation  10 minutes  94º C 
Denaturation  45 seconds  94º C 
Primer annealing  30 seconds  ~5º C below Tm of primers 
Extension  1 min/kb of product  72º C 
Final extension  10 min  72º C 
 
2.1.7. Sequencing 
DNA  sequences  were  verified  using  the  Imperial  College  and  University 
College Sequencing Services, either using standard or customised primers. 
     56 
2.2.  Tissue culture 
2.2.1. Cell lines 
  293T cells were used for viral packaging and testing expression of LVs. They 
are an easily transfectable and highly transgene-expressing cell line derived from 
human embryonic kidney cells, which express the large T antigen of simian virus 40 
(DuBridge et al. 1987; Pear et al. 1993). 293T cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Gibco, Paisley, UK), supplemented with 10% 
Foetal Calf Serum (FCS) (Serotec, Oxford, UK), 2 mM L-glutamine (Gibco), 100 
U/mL penicillin and 100 µg/mL streptomycin (Gibco). Cells were passaged 1:3-1:4 
using trypsin/EDTA (Gibco) every 2-3 days. 
  For the in vitro experiments in which the tetracycline conditional expression 
system was used, media were supplemented with 10% Tet System Approved Foetal 
Bovine Serum (Clontech, Mountain View, CA), free of tetracycline or doxycycline 
traces.  
  RF33  cells,  a  mouse  T  cell  hybridoma  that  expresses  the  T  cell  receptor 
specific for OVA class I epitope SIINFEKL, was cultured in Roswell Park Memorial 
Institute (RPMI, Gibco) medium supplemented with 10 % FCS, 2 mM L-glutamine, 
100 U/mL penicillin and 100 ￿g/mL streptomycin. 
2.2.2. Generation of bone marrow-derived dendritic cells 
  Bone  marrow-derived  DCs  were  produced  as  described  by  Talmor  et  al. 
(1998).  Briefly, the bone marrow of C57BL/6 mice was flushed from leg bones with 
Hank’s buffered salt solution (HBSS, Gibco) using a syringe. After lysing the red 
blood cells and washing twice, the cells were resuspended at 5-7.5 x 10
5 cells/mL in 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco) supplemented with 10% 
FCS, 2 mM L-glutamine,  100 U/mL penicillin, 100 µg/mL streptomycin, 50 µM 2-
mercaptoethanol (Gibco) and 50 ng/mL granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (Peprotech, Rocky Hill, NJ). Medium was replaced every 3 days.     57 
Transductions were performed on day 5-6 with a multiplicity of infection (moi) of 20 
(Palmowski et al. 2004). 
2.3.  Lentiviral vectors 
2.3.1. Vector production 
Vectors  were  produced  by  transient  co-transfection  of  293T  cells  with  a 
transfer vector, a second generation HIV-1 derived packaging plasmid (p8.91) and a 
plasmid encoding the vesicular stomatitis virus glycoprotein (VSV-G) (pMD.G), as 
shown in figure 1.3 and described before (Demaison et al. 2002; Rowe et al. 2006).  
p8.91, pMD.G (Fig. 1.3B-C, respectively) as well as pHRSIN-CSGW and pDUAL-
IiOVA-GFP were produced by Plasmid Factory (Bielefeld, Germany); the rest of the 
plasmids were generated in the laboratory. 
The day before transfection, 10
7 293T cells were plated in 15 cm
2 plates to 
reach a confluency of 80-90% the following day. Transfection was done with Fugene 
6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany) using a mix with 
the following components (amounts per 15 cm
2 plate): 
p8.91        2.5 µg 
pMD.G      2.5 µg 
Transfer plasmid  37.5 µg 
Optimem (Gibco)   500 µL 
Fugene 6       45 µL 
The mix was incubated 15 minutes at room temperature and added dropwise to the 
cells  in  fresh  medium.  The  medium  was  changed  again  24  hours  later.  The 
supernatants were collected after 72 hours and passed through a 45 µm filter.   
The  viral  particles  were  concentrated  100-200-fold  by  two  rounds  of 
ultracentrifugation (115 000 x g for 2 hours at 4º C) in a Sorvall ultracentrifuge, then 
resuspended in HBSS and kept at -80º C until usage.     58 
2.3.2. Transfer constructs 
A schematic representation of the lentiviral transfer plasmids employed is 
shown in Fig. 2.1.  The pHRSIN-CSGW construct (Fig. 2.1A) was provided by A. 
Thrasher and is described in Demaison et al. (2002). This vector is a self-inactivating 
derivative of HIV-1 subtype B, isolate HXB2, with a 400 bp deletion in the 3’LTR 
U3 region. It contains an insert encoding emerald green fluorescent protein (eGFP, 
referred  from  now  on  as  GFP)  driven  by  a  spleen  focus-forming  virus  (SFFV) 
promoter, and a woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE). 
pDUAL-IiOVA-GFP (Fig. 2.1B) was described by Rowe et al. (Rowe et al. 
2006
a). It contains a SFFV promoter that drives expression of a fusion of the C-
terminal  portion  of  the  invariant  chain  and  amino  acids  242-353  of  chicken 
ovalbumin (OVA). The class I H2-K
b-restricted SIINFEKL (OVA257-264) and class II 
H2-IA/IE
b-restricted ISQAVHAAHAEINEAGR (OVA323-339) epitopes are encoded 
within the IiOVA insert. A second promoter, the human ubiquitin promoter (UBI), 
drives the expression of GFP. 
For the Thy1.1 (CD90.1)-encoding vectors (Fig. 2.1C), a Thy1.1 insert was 
amplified by PCR from pMiT (Mitchell et al. 2001), kindly provided by P. Marrack, 
using the primers BamHI-Thy1.1-FW and  Thy1.1-NotI-RV (Table 2.4). The PCR 
product was subcloned into a pGEM-T Easy Vector (Promega) and then into the 
BamHI-NotI  restriction  sites  under  control  of  the  SFFV  promoter  to  generate  
pHRSIN-Thy1.1,  pDUAL-Thy1.1-GFP and pDUAL-Thy1.1-IiOVA.  
The regulatable gene expression LV was kindly provided by O. Danos and 
M. A. Zanta-Boussif. It contains a conditional promoter consisting of a tetracycline 
responsive  element  (TRE)  and  a  cytomegalovirus  minimal  promoter  (CMVmin) 
driving the expression of the insert of interest.  A human phosphoglycerate kinase 
promoter  (hPGK)  drives  constitutive  expression  of  a  tetracycline-responsive 
transactivator (rtTA2
S-M2) (Barde et al. 2006). Upon the presence of tetracycline or 
its  analogue,  doxycycline  (DOX),  the  transactivator  protein  undergoes 
conformational changes, binds to TRE and induces expression of the gene of interest 
(TetOn  system).  GFP  or  IiOVA  cassettes  were  generated  by  PCR  as  MluI-MluI     59 
fragments using MluI-GFP-FW and GFP-MluI-RV, or MluI-IiOVA-FW and IiOva-
MluI-RV primer sets (Table 2.4). The PCR product was subcloned into pGEM-T 
Easy vector and then into the MluI-MluI restriction sites of the LV to generate pSIN-
TRE-GFP-hPGK-rtTA2S-M2 and pSIN-TRE-IiOVA-hPGK-rtTA2S-M2 (Fig. 2.1D). 
Correct  orientation  of  the  insert  in  the  final  constructs  was  verified  by  DNA 
sequencing. 
2.3.3. Site directed mutagenesis of p8.91 
  Two mutations (D185A and D186A) in the highly conserved YMDD motif of 
the  catalytic  core  of  the  reverse  transcriptase  were  introduced  in  the  packaging 
plasmid p8.91 in order to ablate the activity of this enzyme (Kaushik et al. 1996; 
Lowe et al. 1991).  This mutant was generated using the the QuickChange II XL 
Site-Directed  Mutagenesis  Kit  (Stratagene,  La  Jolla,  CA)  and  the  primers  8.91-
RTmut-FW  and  8.91-RTmut-RV  (Table  2.4)  according  to  the  manufacturer’s 
instructions. 
 
 
            Table 2.4. Primers (5’ ￿ 3’). 
 
Name  Sequence 
BamHI-Thy1.1-FW  GGATCCGCCACCATGAACCCAGCCATCAGCG 
Thy1.1-NotI-RV  GCGGCCGCTCACAGAGAAATGAAGTCCAGGG 
MluI-GFP-FW  ACGCGTACCGGTCGCCACCATGGTGAGC 
GFP-MluI-RV    ACGCGTTTTACTTGTACAGCTCGTCC 
MluI-IiOVA-FW  ACGCGTCACTAGTAACGGCCGCCA 
IiOva-MluI-RV  ACGCGTTCACAGGGTGGCAGCATC 
8.91-RTmut-FW  TCCAGACATAGTCATCTATCAATACATGGCAGCA 
TTGTATGTAGGATCTGACTTAGAAATAGG 
 8.91-RTmut-RV  CCTATTTCTAAGTCAGATCCTACATACAATGCTGC 
CATGTATTGATAGATGACTATGTCT GGA     60     61 
2.3.4. Viral titration 
  Viral titers were measured with the following methods: 
2.3.4.1.  Expression of GFP in 293T cells 
  For GFP-encoding LVs, 2 x 10
5 293T cells were transduced with 25 µL of 
serial 1:5 dilutions of lentivectors in 24-well plates. 72 hours later, the percentage of 
GFP-expressing cells was determined by FACS.  Using a sample with 10-30% of 
transduced cells, the titer was calculated as follows: 
 
Viral titer (iu/mL) = 2 x 10
5 cells x % transduced cells x (dilution factor / 25 µL) x 1000 
 
Titers of concentrated virus typically ranged between 10
8-10
9 iu/mL. 
2.3.4.2.  Quantification of reverse transcriptase 
  The  concentration  of  reverse  transcriptase  (RT)  was  measured  using  a 
Reverse  Transcriptase  Assay  colorimetric  kit  (Roche),  according  to  the 
manufacturer’s  instructions.  For  this  assay,  concentrated  virus  was  diluted  1:20-
1:100 and incubated for 3 h for the RT reaction. In general, a correlation of ~10
5 
iu/ng RT was observed between these to titration methods. 
2.3.4.3.  Quantification of p24 
  Concentration of p24 was measured by ELISA using a QuickTiter Lentivirus 
Quantitation Kit HIV p24 (Cell Biolabs, San Diego, CA). Concentrated viruses were 
diluted 1:500. This titration method was only used for experiments involving viruses 
containing the inactive mutant of RT. 
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2.4.  In vivo and ex vivo experiments 
2.4.1. Mice 
C57BL/6 mice were bred in UCL Biological Services facilities and used at 6-
8 weeks of age. OT-1 mice were a kind gift of A. Noble (King’s College of London) 
and  then  bred  in  UCL  facilities.  Animal  experiments  were  performed  with  local 
ethical  approval,  following  institutional  guidelines  and  under  UK  Home  Office 
License. 
2.4.2. Immunisations 
Mice  were  injected  with  10
8  iu  or  500  ng  RT  LVs  (unless  otherwise 
specified), or its equivalent in ng p24, either intravenously (iv) or subcutaneously 
(sc). Negative controls were injected with PBS. Some mice were also injected with 
50 µg of OVA class I peptide (SIINFEKL, Proimmune, Oxford, UK) plus 30 µg of 
monophosphoryl lipid A (MPL, Sigma-Aldrich, St. Louis, MO) as adjuvant, both iv. 
2.4.3. Harvesting spleens 
  Spleens were collected in HBSS and mashed through a 70 ￿m nylon mesh 
(BD Falcon). Cells were washed in HBSS containing 2% FCS, resuspended in red 
blood  cell  lysis  buffer  (Sigma-Aldrich)  for  5  minutes  at  room  temperature  and 
washed twice before using.  
2.4.4. Splenectomies 
Mice were anaesthetised with 5% isoflurane and maintained with 1-3% of the 
same anesthetic gas. In aseptic conditions, spleens were removed through a subcostal 
incision. Bleeding was controlled by electrocauterisation.  The incision was sutured 
in  two  layers.  The  animals  were  recovered  at  37°C  and  closely  monitored 
immediately  and  the  days  after  the  procedure.  For  pain  control,  0.1  mg     63 
buprenorphine was injected sc 30 minutes before anaesthesia and every 12 hours 
thereafter, or upon distress signs. 
2.4.5. Purification of dendritic cells from spleens 
Spleens were collected, cut into small pieces and then incubated in a solution 
of 2 mg/mL collagenase IV (Worthington, Lakewood, NJ) and 10 mM Hepes buffer 
(Gibco) in HBSS for 30 minutes at 37°C. Splenocytes were obtained as described 
before.  Fc  receptors  (FcR)  were  blocked  with  an  anti-mouse  FcR  (CD16/32) 
antibody produced in house from a rat hybridoma cell line. DCs were purified by 
positive  selection  using  magnetic  CD11c  (N418)  microbeads  (Miltenyi  Biotec, 
Auburn, CA) according to manufacturer’s instructions.  
2.4.6. Surface staining for flow cytometry 
  Cell  surface  staining  was  performed  on  ice  and  with  ice-cold  buffers. 
Incubations were done in the dark. The antibodies employed and their respective 
dilutions  are  shown  in  table  2.5.  An  additional  blocking  step  with  anti-FcR  and 
HBSS with 10% mouse serum (Serotec) was done for 20 minutes prior to staining 
DCs or before using anti-Thy1.1 to reduce unspecific antibody binding.  
Each sample (1-5 x 10
6 cells) was stained in a volume of  50 ￿L (96-well 
plate) or 100 ￿L (FACS tube). Antibodies were diluted in staining buffer (HBSS, 2% 
FCS,  0.1%  sodium  azide),  incubated  for  30  minutes  and  washed  twice.  When 
needed,  samples  were  labelled  with  stretavidin-conjugated  fluorochromes  for  20 
minutes.  Cells  were  fixed  with  Cytoperm/Cytofix  solution  (BD  Biosciences)  and 
resuspended  in  HBSS  with  sodium  azide  0.1%.  Fluorescence  activated  flow 
cytometry (FACS) was done using either FACScalibur or LSR flow cytometers (BD, 
San José, CA). The results were analysed using CellQuest (BD) or FlowJo 7.5 (Tree 
Star Inc., Ashland, OR) softwares. 
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Table 2.5. Antibodies for FACS. 
 
Antibody  Clone  Company  Dilution 
CD3-APC  145-2C11  eBioscience  1:100 
CD4-PE  GK1.5  eBioscience  1:200 
CD4-PECy7  GK1.5  eBioscience  1:200 
CD8a-APC  53-6.7  eBioscience  1:200 
CD8a-PE  53-6.7  eBioscience  1:200 
CD11c-APC  HL3  BD Pharmingen  1:400 
CD11c-biotin  HL3  BD Pharmingen  1:400 
CD19-PE  6D5  eBioscience  1:200 
CD40-biotin  1C10  eBioscience  1:100 
CD44-APC  IM7  eBioscience  1:100 
CD80-biotin  16-10A1  eBioscience  1:100 
CD86-biotin  B7-2  BD Pharmingen  1:100 
F4/80-PE  BM8  eBioscience  1:500 
Gr-1 (Ly-6G)-PECy7  RB6.8C5  eBioscience  1:200 
IFN￿-APC  XMG1.2  BD Pharmingen  1:100 
MHC-II (IA/IE
b)-PE  M5/114.15.2  eBioscience  1:1000 
MHC-II (IA
b)-FITC  AF6-120.1  BD Pharmingen  1:1000 
PDCA-1-PE  JF05-1C2.4.1  Miltenyi  10 ￿L/sample 
Thy1.1 (CD90.1)-PE  HIS51  eBioscience  1:500 
Thy1.1 (CD90.1)-biotin  HIS51  eBioscience  1:500 
V￿2-PE  Cat# RM5004  Caltag  1:200 
V￿5.1, 5.2-biotin  MR9-4  BD Biosciences  1:200 
Isotype controls 
Hamster IgG-biotin  G235-2356  BD Pharmingen  1:200 
Mouse-IgG2a-biotin  M2a  eBioscience  1:200 
Rat IgG2a-biotin  R35-95  BD Pharmingen  1:200 
Streptavidin conjugates 
sva-FITC    DakoCytomation  1:500 
sva-PE    eBioscience  1:500 
sva-APC    eBioscience  1:500 
sva-PECy7    eBioscience  1:500 
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2.4.7. BrdU labelling 
To label in vivo dividing cells, mice were injected intraperitoneally (ip) with 
200  µg  of  5-bromo-2’-deoxyuridine  (BrdU,  Sigma-Aldrich)  in  HBSS  and  then 
continuously given BrdU (0.8 mg/mL) in drinking water, that was changed daily. 
Experiments were terminated after 10 days of BrdU administration. Then spleens 
were  harvested  and  CD11c
+  cells  were  purified  using  magnetic  microbeads  as 
described before. CD11c
+ and CD11c
- cells were stained for surface markers and 
nuclear BrdU using a BrdU Flow Kit (BD Biosciences, San Diego, CA) according to 
the manufacturer’s instructions. In brief, after surface antigen staining, cells were 
fixed and permeabilised with Cytofix/Cytoperm (BD Biosciences). Then they were 
treated with 300 µg/mL of DNase I (Worthington) in DPBS (Gibco) for one hour at 
37°C, washed, re-blocked with 10% mouse serum and stained with an APC-labelled 
anti-BrdU antibody for FACS analysis. 
2.4.8. CFSE labelling and adoptive transfer of OT-1 cells 
Spleen cells from OT-1 mice were resuspended at 5-10 x 10
6 cells/mL in 
HBSS  plus  0.1%  bovine  serum  albumin  and  then  labelled  with  5  µM 
carboxyfluorescein  succinimydil  ester  (CFSE,  Invitrogen,  Carlsbad,  CA)  for  10 
minutes at 37°C.  5-10 x 10
6 CFSE-labelled cells were transferred iv into immunised 
and control C57BL/6 mice. Five days later they were tracked by FACS in peripheral 
blood mononuclear cells (PBMCs) or in spleens after staining with antibodies against 
the V￿2 (Caltag) and V￿5.1, 5.2 (BD Pharmingen) chains of the T cell receptor. Cell 
proliferation was quantifed by  FACS by measuring dilution of CFSE in labelled 
cells. 
2.4.9. Enzyme-linked immunospot assay 
Enzyme-linked  immunospot  assay  (ELISpot)  plates  (Millipore,  Billerica, 
MA) were covered overnight with 10 ￿g/mL of purified anti-IFN￿ (BD Pharmingen, 
San Diego, CA) at 4ºC overnight. The day after, the plate was washed and blocked 
for at least 2 hours with RPMI medium with 2% FCS, 2 mM L-glutamine, 100 U.mL     66 
penicillin and 100 µg/mL streptomycin.  Splenocytes were resuspended in RPMI and 
added in different amounts per well (usually 5 x 10
5 or 1 x 10
6, in duplicates). The 
plate was incubated for 20-24 hours at 37ºC, either in the presence of 50 ng/mL OVA 
class I peptide (SIINFEKL, Peprotech, Rocky Hill, NJ) or medium alone. The day 
after, the cells were washed and IFN￿ production was determined with 0.5 mg/mL 
biotinilated anti-IFN￿  antibody (BD Pharmingen), 1:10000 streptavidin-conjugated 
alkaline  phosphatase  (Caltag,  Burlington  CA)  and  an  Alkaline  Phosphatase 
Conjugate Substrate Kit (BioRad, Hercules, CA). Spots were counted using AID 
ELISPOT counter and software. 
2.4.10.  Pentamer staining 
  Blood  samples  were  collected  in  tubes  with  heparin  and  diluted  1:5  with 
HBSS.  PBMCs  were  obtained  by  density  separation  using  M-Lympholyte 
(Cedarlane, Canada) following the manufacturer’s instructions. Cells were stained 
with APC-conjugated anti-CD8 and washed twice. Then 10 ￿L of PE-conjugated 
MHC Pentamer H2-K
b SIINFEKL (Proimmune, Oxford, UK) were added to each 
sample and incubated for 10 minutes at room temperature.  Cells were washed twice 
and resuspended in running buffer for FACS. 
2.4.11.  In vivo cytotoxicity assays 
Spleen cells from naïve mice were resuspended in HBSS (5 x 10
6 cells/mL) 
and pulsed with OVA257-264 peptide (5 µg/mL) during 2 hours at room temperature. 
Then they were labelled with 10 µM CFSE as described before. They were mixed in 
a  1:1  ratio  with  non-pulsed  cells,  labelled  with  3  µM  CFSE.    The  mixture  was 
injected in control and immunised mice at different time points.  Specific lysis of the 
pulsed cells was analysed 18 hours later by FACS in cells isolated from peripheral 
blood  or  from  the  spleen.    The  percentage  of  killing  was  calculated  with  the 
following formula:   
 
1-[(% CFSE
high/%CFSE
low)immunised/(%CFSE
high/%CFSE
low)non immunised]     67 
2.4.12.  Isolation of transduced DCs with magnetic microbeads 
Isolation of tranduced DCs in the spleen was done based on expression of 
Thy1.1  and  using  an  Anti-biotin  Multisort  magnetic  separation  kit  (Miltenyi) 
according to the manufacturer’s instructions. Briefly, splenocytes of mice injected 
with Thy1.1-GFP or Thy1.1-IiOVA LV at different time points (5 or 30 days before 
the experiment) were prepared as described before and labelled with anti-CD11c-
biotin and anti-Thy1.1-PE antibodies. In a first positive selection step, CD11c
+ cells 
were  purified  using  anti-biotin  detachable  microbeads.  After  releasing  these 
magnetic  particles  with  a  “release  buffer”,  cells  were  labelled  with  anti-PE 
microbeads to separate CD11c
+Thy1.1
+ cells.  The purity of the final samples ranged 
from 60 to 70% of CD11c
+Thy1.1
+ cells. However, a population of CD11c
hiThy1.1
- 
cells  was  observed  in  two  separate  experiments,  from  which  the  anti-biotin 
microbeads probably did not detach.  
The obtained cells were used forex vivo antigen presentation assays or DC 
transfer experiments.  
2.4.13.  Ex vivo antigen presentation assays 
DCs isolated from spleens of mice injected with IiOVA-GFP or GFP LVs 
were co-cultured with splenocytes from OT-1 mice or T cell hybridoma RF33.  
In the case of the DC/OT-1 co-culture, 5 x 10
5 isolated DC were plated in 
each  well  of  an  ELISpot  plate.  The  experiments  were  done  both  using  frozen 
expanded CD8
+ T cells (Rowe, 2006
a) and with total splenocytes from OT-1 mice. 
The DC:OT-1 ratios ranged from 10:1 to 1:1.  Antigen presentation was measured by 
IFN-￿ spot count after 20-hour incubation in the presence of peptide (SIINFEKL, 50 
ng/mL) or medium. 
In the case of the DC/RF33 co-cultures, 5 x 10
4 RF33 cells were cultured 
overnight with different numbers of DCs (5 x 10
4 – 1 x 10
3) in 96-well plates, in the 
presence of SIINFEKL (10 ng/mL) or medium.  To measure antigen presentation, 
IL-2 was quantified in the supernatants by ELISA (eBioscience, San Diego, CA). 
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2.4.14.  DC transfer experiments 
Spleen DCs from mice injected with LVs or with PBS at different time points 
(5 or 30 days before the experiment) were transferred to naïve mice and tested for 
their ability to generate a progeny of transgene-expressing DCs or to present antigen 
in the recicipents.  For the first, 3-5 mice were injected with Thy1.1-LV iv and either 
CD11c
+, Thy1.1
+ or CD11c
+Thy1.1
+ cells were purified from their spleens using 
magnetic microbeads as described above. Up to 5 x 10
6 DCs, 2 x 10
6 Thy1.1
+ cells, 
or  1  x  10
6  CD11c
+Thy1.1
+  cells  were  trasferred  iv  to  naïve  mice  in  separate 
experiments. Three days later, DCs were purified from the spleens of the recipient 
mice and stained with anti-Thy1.1 to identify transduced cells.  
For the second, DCs of mice injected iv with IiOVA-GFP LV, GFP LV or 
PBS at different time points (5 or 30 days) were purified from the spleen and injected 
(5 x 10
6 ) sc or iv in naïve mice. The immune response was evaluated by IFN-￿ 
ELISpot ten days later. 
2.4.15.  Western blots 
  Buffers and solutions for Western blots are shown in table 2.6. Total cell 
lysates  were  prepared  with  1%  Igepal  (Sigma-Aldrich)  solution,  resuspended  in 
Laemmli  buffer  and  heated  at  96º  C  for  5  minutes.  Volumes  were  standardised 
according  to  protein  concentrations.  Proteins  were  separated  by  SDS-PAGE 
electrophoresis  using  4%  polyacrylamide  stacking  gels  and  11%  polyacrylamide 
separation  gels,  in  SDS  running  buffer  at  150  volts.  Proteins  were  blotted  onto 
Hybond ECL nitrocellulose membrane (Amersham GE Healthcare, Buckinhamshire, 
UK) using semi-dry transfer (Pharmacia Biotech) in the presence of transfer buffer, 
at 300 mA for 45 minutes. Membranes were blocked 1 h with blocking buffer at 
room temperature and probed overnight with a polyclonal rabbit anti-OVA antibody 
(1:500 in blocking buffer) at 4ºC. The membrane was washed three times with PBS 
plus  0.1%  Tween  20  before  adding  anti-rabbit  horseradish-peroxidase  (HRP)-    69 
conjugated  antibody  (DakoCytomation,  Glostrup,  Denmark)  diluted  1:3000  in 
blocking buffer. Membranes were washed twice with PBS plus 0.1% Tween 20, once 
with  PBS,  and  developed  with  ECL  substrate  reagents  and  Hyperfilm  ECL 
(Amersham GE Healthcare). 
2.4.16.  Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5.0. Means were compared 
using T-student or Mann-Whitney tests, as indicated in each experiment. 
 
 
 
Table 2.6. Buffers and gels for Western blots. 
 
Buffer/gel  Composition 
Laemmli buffer  2% sodium duodecylsulphate (SDS), 10% glycerol, 
5% 2-mercaptoethanol,  0.2 mg/mL bromophenol 
blue, 0.1 M DTT 50 mM Tris (pH 6.8) 
11% polyacrylamide gel  11% acrylamide/bis, 125 mM Tris.HCl (pH 8.8), 
10% SDS, 0.1% TEMED, 1% ammonium 
persulphate (APS) 
4% stacking gel  4% acrylamide/bis, 125 mM Tris.HCl (pH 6.8), 10% 
SDS, 0.1% TEMED, 1% APS 
Running buffer  25 mM Tris (pH 8.5), 200 mM glycine, 0.1% SDS 
Transfer buffer  100 mM Tris, 200 mM glycine, 20% methanol 
Blocking buffer  5% semi-skimmed milk, 0.1% Tween 20 in PBS     70 
  
CHAPTER 3 
3. LONG-TERM TRANSGENE EXPRESSION IN 
LENTIVECTOR –TRANSDUCED ANTIGEN 
PRESENTING CELLS 
3.1.  Introduction 
  It has been shown that after systemic administration, LV integrants persist in 
the bone marrow, liver and spleen (Pan et al. 2002).  In the liver and spleen, these 
vectors transduce APCs, which explains the immune responses against the delivered 
transgene that are observed after intravenous injection (VandenDriessche et al. 2002; 
Palmowski et al. 2004).  
There is evidence that expression of LV-delivered transgenes persist in these 
cells for months (VandenDriessche et al. 2002; Kimura et al. 2007).  In the steady 
state,  the  longevity  of  different  APC  subpopulations  differs.  Macrophages  in  the 
mouse spleen are mostly long-lived cells (Wijffels et al. 1994). In contrast, DCs have 
a rapid turnover and an average half-life of 2-3 days (Kamath et al. 2002). Even the 
relatively long-lived plasmacytoid DC subset has a lifespan of 14 days (O' Keeffe et 
al. 2002). This raises the question of how is the population of LV-modified APCs 
maintained in spleen for several months. 
Much  of  the  research  on  LVs  as  vaccine  vectors  has  focused  on  genetic 
modification  of  DCs  because  of  their  functional  plasticity  and  efficient  antigen 
presentation ability of (Banchereau & Steinman 1998). Considering the interest on 
these cells, the following sections will analyse some aspects of the DC biology in 
more detail.  Since this thesis is based on a murine model, most of the information 
will refer to the mouse system, unless otherwise specified.     71 
3.1.1. DC classification 
  DCs  comprise  a  widely  distributed  network  of  cells  that  vary  in 
haematological  origin,  life  cycle  and  functional  properties.  They  share  common 
specialised features that allow them to be grouped in a single family: (1) they possess 
all the necessary machinery to pick up, process and present antigens to T cells, (2) 
they have migratory competence and (3) they are capable of sensing and translating 
environmental signals into information that ultimately dictates the fate of T cells 
(Reis e Sousa 2006; Steinman & Banchereau 2007; Shortman & Liu 2002). 
  DCs can be classified according to different criteria, including developmental 
stage, life history, anatomical location, presence in a steady-state or inflammatory 
environment, activation status and into different subtypes based on several markers 
(Naik 2008). Figure 3.1 shows a general classification of DCs according to these 
criteria.  
3.1.1.1.  Conventional DCs 
  Conventional DCs (cDCs) are fully differentiated cells that present the typical 
DC morphology and function in the steady state. Based on their life history, cDCs 
can be divided into migratory or resident DCs. The subclassification of cDCs and 
their frequency in different lymphoid organs is shown in Table 3.1. 
3.1.1.1.1.  Migratory DCs 
  This  population  of  DCs  are  found  in  the  periphery  (e.g.,  skin,  mucosae), 
where  they  function  as  antigen-sampling  sentinels.  They  migrate  to  the  regional 
draining  lymph  nodes  via  afferent  lymphatic  vessels.    During  the  steady  state, 
migration occurs at a basal rate and is important for the maintenance of peripheral 
tolerance (Hemmi et al. 2001). In the presence of ‘danger’ signals, DCs migrate to 
secondary lymphoid organs and progressively mature.  Maturation is accompanied 
by an increase in the antigen presentation ability and loose of migratory capacity 
(Reis e Sousa 2006).      72 
  This category of DCs include the epidermal Langerhans cells (CD11c
+ MHC-
II
+ langerin
+) and interstitial DCs (CD11c
int MHC-II
hi DEC-205
int), present in the 
mucosae and in the dermis, some of which also express langerin. These cells serve 
two  functions:    transportation  of  the  antigen  to  the  lymph  node  and  antigen 
presentation to cognate T cells.  Some studies have suggested that Langerhans cells 
are not directly involved in T cell priming but only in the transport of antigen to the 
lymph node, where it is captured and presented by resident DCs (Allan et al. 2003; 
Zhao et al. 2003). It has been proposed that these cells are potentially dispensable for 
the  priming  of  the  immune  response  (Brewig  et  al.  2009;  Henri  et  al.  2007). 
Therefore,  more  research  is  necessary  to  clarify  their  role  as  APCs.    Instead, 
interstitial  DCs  have  been  involved  in  T  cell  priming  during  hypersensitivity 
responses (Bennett et al. 2007) and certain infections, including HSV-2 (Zhao et al. 
2003) and cutaneous leishmaniasis (Brewig et al. 2009; von Stebut et al. 2000).  
3.1.1.1.2.  Resident DCs 
  This group refers to DCs that reside in lymphoid organs, where they collect 
and present foreign and self antigens. They can be divided in subsets that differ in 
anatomical location, function and expression of CD4, CD8￿, CD11b and DEC-205, 
among other markers (Table 3.1) (Shortman & Liu 2002).  
  CD8￿
+ cDCs are concentrated in the T cell areas of the spleen and lymph 
nodes  (Naik  2008).  This  anatomical  location  reflects  the  importance  of  their 
interaction with T cells, on which they exert two opposite effects.  In the steady state, 
CD8￿
+ DCs play an important role in generating peripheral tolerance (Belz et al. 
2002). Yamazaki et al. (2008) have shown that these cells induce IFN-￿-dependent 
generation of regulatory T cells (Treg).   
On the other hand, activated CD8￿
+  DCs are  potent initiators of immune 
responses and are the main T cell-priming APC in some infections (Smith et al. 
2003). They have a high expression of TLR3 but not of TLR7, which suggests they 
preferentially  recognise  double-stranded  RNA  (Rizzitelli  et  al.  2005).  Upon 
activation,  they  produce  large  amounts  of  IL-12p70,  which  is  crucial  for  the 
generation  of  CD4
+  TH1  responses,  cytotoxic  CD8
+  T  cells  and  memory  T  cells     73 
(Maldonado-López et al. 1999). CD8￿
+ DCs also have a superior ability for cross-
presentation  (den  Haan  et  al.  2000;  Pooley  et  al.  2001),  which  explains  their 
important role in the immune response against viral infections (Heath et al. 2004). 
  CD8￿
- cDCs are present in the marginal zones of lymph nodes and spleen, 
but migrate to the T cell areas upon activation. These cells are also potent T cell 
primers, but tend to polarise CD4
+ T cells towards a TH2 response  (Maldonado-
López  et  al.  1999).  CD8￿
-  DCs  can  be  subdivided  into  CD4
+  and  CD4
-.  The 
difference between these two subpopulations is not completely  understood. CD8
- 
CD4
- DCs are thought to be an important source of IFN-￿ during immune responses 
(Hochrein  et  al.  2001)  and  can  also  produce  enough  IL-12p70  to  elicit  a  TH1 
response (Shortman & Liu 2002). 
  In spite of the differences between DC subsets, these cells display a great 
plasticity in directing TH development.  The same DC subset can trigger a TH1 or 
TH2-polarised response depending on other factors besides their phenotype, such as 
the type of stimulus they receive (Manickasingham et al. 2003). 
3.1.1.2.  DC ‘immediate’  precursors 
  The DC population also includes its ‘immediate’ precursors, which are the 
last  stage  en  route  to  DC  differentiation.  These  cells  do  not  have  dendritic 
morphology or full DC function, but they develop into DCs with little or no cell 
division. The final differentiation steps can take place spontaneously in the steady 
state, or may require some additional stimulus, such as inflammation or infection 
(Shortman  &  Naik  2007).  This  category  includes  monocytes,  plasmacytoid  DCs 
(pDCs) and DC precursors that differentiate into resident DCs (pre-DCs). 
3.1.1.2.1.  Monocytes as precursors of DCs 
Monocytes are cells from the mononuclear phagocytic system that are present 
in circulation and in several organs. They derive from a common macrophage-DC 
precursor (MDP) of myeloid origin, from which a monocyte/macrophage precursor 
(MMP) originates and differentiates into monocytes. In the mouse, there are two 
monocyte subpopulations:  non-inflammatory Ly6C
low and inflammatory Ly6C
high.     74 
These correspond to human CD14
+ and CD16
+CD14
+ monocytes, respectively (Naik 
2008).   
For a long time monocytes were thought to be the principal DC precursors 
mainly because in vitro they can differentiate into CD11c
highMHC-II
+CD8
- DCs in 
the presence of GM-CSF (± IL-4). However, in vivo, the role of monocytes and GM-
CSF in the generation of DCs in the steady state is controversial. The evidence so far 
indicates that monocytes differentiate into DCs in some tissues only under certain 
circumstances (Randolph et al. 1999; Varol et al. 2007) and that Ly6C
high monocytes 
can differentiate into inflammatory DCs (Serbina et al. 2003). 
3.1.1.2.2.  Plasmacytoid DCs (pDCs) 
pDCs are a widely distributed type of DCs,  found in the blood, thymus, BM, 
liver and T cell areas of lymphoid organs. (Asselin-Paturel et al. 2003). They have a 
round morphology and low expression of MHC and T cell co-stimulatory molecules, 
which renders them with a poor antigen presentation ability. Upon stimulation, they 
acquire dendritic morphology and upregulate expression of MHC and co-stimulatory 
molecules. Thus,  circulating pDCs  are considered DC immediate precursors, i.e., 
they must undergo a few divisions and differentiation steps to become mature DCs 
(Shortman & Naik 2007).  
pDCs  can  be  identified  by  expression  of  several  markers:  CD11c
low  Gr-
1(Ly6G)
+  B220(CD45R)
+  CD4
+  CD8￿
-  CD11b
-  PDCA-1
+  (O' Keeffe  et  al.  2002; 
Villadangos & Young 2008). However, the most characteristic feature of these cells 
is  their  ability  to  produce  large  amounts  of  type  I  IFN  upon  viral  infection  or 
stimulation with viral nucleic acid motifs, such as unmethylated CpG motifs and 
viral  RNA  (Asselin-Paturel  et  al.  2001;  Grouard  et  al.  1997;  Björck  2001).  The 
response  to  these  pathogens  seems  to  depend  on  a  discrete  number  of  TLRs—
particularly TLR-7 and TLR-9—as well as probably other PRRs (Kadowaki et al. 
2001). Type I IFNs play an important role in the resistance to viral infections.  They 
act as survival factors for pDCs, enhance the maturation and antigen cross-priming 
ability of cDCs, induce secretion of chemokines and cytokines, activate natural killer     75 
cells and macrophages, and are involved in the generation of memory CD8
+ T cells 
(Fitzgerald-Bocarsly & Feng 2007). 
In spite of the controversy in the past years regarding the capacity of pDCs to 
present antigen to T cells, it is now consensus that they can prime T cells with the 
same  immunogenic  or  tolerogenic  outcomes  observed  with  cDCs.  However,  the 
MHC-II/peptide complexes in pDCs are not as long-lived as in cDCs and they are 
less efficient in cross-presenting antigen. These two traits make of pDCs a weaker 
APC as compared with cDCs (Villadangos & Young 2008). 
3.1.1.3.  Inflammatory DCs 
A different subpopulation of DCs, called inflammatory DCs (iDCs), emerges 
during inflammatory processes.  These cells characteristically produce TNF-￿ and 
inducible nitric oxide synthase (iNOS) and display CD11c
intCD11b
highMAC-3
+, as 
opposed to the CD11c
high CD11b
lowMAC-3
- steady-state spleen DCs.  (Serbina et al. 
2003).  iDCs have a different ontogeny from that of cDCs since they derive from 
circulating  Ly6C
hi  monocytes  through  GM-CSF  stimulation.  Indeed,  their 
development  can  be  modelled  in  vitro  by  culture  of  BMDCs  with  this  cytokine 
(Shortman & Naik 2007).  Regarding their function, iDCs mediate innate immune 
responses against bacteria (Serbina et al. 2003) and have recently been shown to play 
an important role in generating TH1-polarised responses to certain infections (Nakano 
et al. 2009).      76     77 
3.1.2. DC turnover and homeostasis 
  DCs are short lived cells. Therefore, their homeostasis depends on constant 
replacement  by  new  cells  that  derive  from  dividing  precursors.    This  has  been 
demonstrated by using in vivo BrdU incorporation as an indicator of cell division and 
turnover.  These studies have shown that DC turnover rates differ among lymphoid 
organs and DC subsets (Table 3.2) (Kamath et al. 2000; Kamath et al. 2002; Ruedl et 
al. 2000). In the steady state, spleen DCs have a half life of 2-3 days. The CD8￿
+ 
subpopulation has a higher turnover than other cDC subsets. Furthermore, the life 
span  of  DCs  is  shortened  by  approximately  one  third  upon  antigen  capture  and 
maturation (Kamath et al. 2002).  
The identification of the stages of differentiation and commitment to specific 
DC lineages has been a matter of debate. Although DC ontogeny is not completely 
understood, some precursors have been identified in the past decade. 
3.1.2.1.  Early DC precursors 
All DC subpopulations derive from bone marrow haematopoietic progenitors.  
Both common lymphoid precursors (CLPs) and common myeloid precursors (CMPs) 
can give rise to all DC subpopulations. Commitment to the DC lineage seems to 
depend on the expression of the transcription factor fms-related tyrosine kinase 3 
(Flt3) and its binding by Flt3 ligand (Flt3L)  (Karsunky et al. 2003; Onai et al. 2007; 
Waskow et al. 2008).  CD8￿
+ and CD8￿
- cDCs, as well as pDCs, can be generated in 
vitro by culture of bone marrow cells in the presence of Flt3L. This cytokine plays an 
important  role  in  maintaining  DC  homeostasis  in  the  steady  state  and  during 
inflammation,  since  it  increases  the  number  and  mobilization  of  DCs  to  the 
periphery. Nevertheless, the presence of some DC subpopulations in Flt3
-/- mice and 
absence of Flt3 expression in some precursors suggests that other factors must be 
involved in DC development (Tan & O' Neill 2007). 
The  majority  of  DCs  seem  to  derive  from  myeloid  precursors,  probably 
because their larger number in the bone marrow (Shortman & Naik 2007). Liu et al.     78 
(2009)  have  recently  characterized  the  progress  of  DC  development  from  early 
myeloid precursors, which give rise to monocytes, pDCs and pre-cDCs (Figure 3.2).  
This and other studies arrive to the following conclusions: (1) cDCs derive from 
precursors (pre-cDCs) that originate in the bone marrow and migrate to peripheral 
lymphoid organs, where they undergo their final differentiation steps; (2) monocytes 
diverge  from  the  cDC  lineage  in  the  transition  from  a  common  macrophage-DC 
precursor (MDP) to a common DC precursor (CDP) in the bone marrow; they leave 
the  bone  marrow  and  can  differentiate  into  macrophages  or,  in  presence  of 
inflammation, into DCs; (3) there is so far no identification of a committed pDC 
precursor in the periphery; instead, pDCs leave the bone marrow and progressively 
acquire maturation markers in the bloodstream and peripheral lymphoid organs (Diao 
et al. 2006; Liu et al. 2007; Liu et al. 2009; O' Keeffe et al. 2003; Shortman & Naik 
2007). 
In  contrast  to  other  haematopoietic  cells,  differentiation  of  DCs  does  not 
seem to be a linear process where specific precursors are restricted to give origin to a 
particular cell type.  Instead, they can differentiate into one or other lineage at every 
stage of differentiation depending on factors that are still not completely understood 
(Naik 2008). 
3.1.2.2.  Immediate DC precursors 
    In  the  past  few  years,  a  broadly  distributed  population  of  committed  DC 
precursors (pre-DC) has been identified in lymphoid organs and in circulation. In the 
steady state, these pre-DCs differentiate in situ into cDCs after 0-3 cell divisions.  
They are also detected in inflamed tissues and may be important to increase the local 
number  of  DCs  in  situations  where  more  antigen  processing  and  presentation  is 
required (Diao et al. 2006; Naik et al. 2006; del Hoyo et al. 2002). 
In  the  spleen,  pre-DCs  constitute  a  small  population  (0.05%)  that  can 
generate  all  the  resident  cDC  subsets  from  this  organ,  but  not  pDCs.  They  are 
characterised by an intermediate expression of CD11c, no expression of MHC-II, 
absence of lineage markers (CD4, CD8, B220, CD3, CD19, Gr-1, F4/80, DX5), and 
intermediate expression of CD43 and signal-regulatory protein (SIRP)-￿ (Naik et al.     79 
2006).  Equivalent  cells  have  been  identified  in  bone  marrow,  thymus,  Peyer’s 
patches and lymph nodes (Diao et al. 2006).  
  Pre-DCs can be divided in two subpopulations.  CD24
+ pre-DCs give rise to 
CD8￿
+ cDCs, while CD24
- pre-DCs give origin to CD8￿
- cDCs (Fig. 3.1) (Naik et 
al. 2006). However, the ontogeny of CD8
- CD4
- and CD8
- CD4
+ is not clear yet.     80 
Table 3.1.  Frequency of DC subtypes in different lymphoid organs
a. 
 
Resident cDCs  Intestitial 
DCs 
Langerhans 
cells  Lymphoid 
organ 
CD8
+ CD4
- 
CD205
+ 
CD11b
- 
CD8
- CD4
+ 
CD205
- 
CD11b
+ 
CD4
- CD8
- 
CD205
- 
CD11b
+ 
CD4
- CD8
- 
CD205
+ 
CD11b
+ 
CD4
- CD8
lo 
CD205
hi 
CD11b
+ 
Spleen  23  56  19  <4  <1 
Thymus  70         
Mesenteric 
LN  19  4  37  26  <4 
Skin
-
draining LN  17  4  17  20  33 
 
a Percentages of each subpopulation in the indicated organ. 
Reproduced from Shortman & Liu. Nature Reviews Immunology. 2002. 2(3): 151-161, 
with permission of the publisher. 
 
 
Table 3.2. Half life
a of DC subpopulations in the spleen and 
lymph nodes (LN) based on BrdU incorporation. 
 
DC subset  Spleen  Mesenteric 
LN 
Skin-
draining LN 
Total DCs  3  3.5  10 
CD8
+ CD4
-  1.5  3  7 
CD8
- CD4
+  2.9     
CD8
- CD4
-  3  3.1  9 
Interstitial    4
b  11
b 
Langerhans cells      21
b 
 
a  Half life defined as the number of days required for incorporation of 
BrdU in 50% of the population. 
b Since these cells are migratory, these values reflect the total half life of 
the cell population and not the half life in the lymph node, which is 
shorter (2-3 days) (Kamath et al. Blood, 2002. 100(5) : 1734-1741).     81     82 
  DC transduction by LVs is thought to be instrumental for the generation of an 
immune response to the transgene. The characterisation of different cell subtypes 
transduced in vivo has not been studied in detail, and the persistence of expression in 
APCs remains unclear. This is important to understand the immune responses or 
possible risks associated with LVs. 
3.1.3. Aims 
·  Characterise the different subpopulations of cells transduced in the mouse 
spleen after systemic administration of LVs. 
 
·  Determine whether APCs maintain expression of the transgene over time and 
the possible reasons for this. 
 
3.2.  Results 
3.2.1. Long term GFP expression in DC subsets in the spleen 
  Previous studies have shown that expression of reporter genes can be detected 
in the lymph node after subcutaneous injection of LVs (Lopes et al. 2008) and in the 
spleen after intravenous administration (Rowe et al. 2006; Palmowski et al. 2004).  
However, no transgene expression can be detected in the lymph node after 10 days 
(Dullaers et al. 2006), probably because of the short half life or migration patterns of 
targeted cells. Instead, transduced cells persist for a longer time in the liver, spleen 
and bone marrow after intravenous administration (Pan et al. 2002; VandenDriessche 
et al. 2002).  
Firstly,  the  transduction  of  different  APC  subpopulations  in  the  spleen 
following  intravenous  LV  injection  was  analysed.  In  these  experiments,  a  LV 
expressing GFP and a second IiOVA-GFP LV expressing GFP and an ovalbumin 
fragment fused with the invariant chain were used (Fig. 2.1A-B). GFP expression 
was then examined both in the short term (5 days) and in the long term (30 days) in     83 
different cells populations in the spleen. Figure 3.3 shows results with the GFP LV; 
although all the DC subsets present in the spleen were transduced, the percentage 
was highest in the CD4
+ CD8
- subpopulation (Fig. 3.3A), which is also the most 
abundant in the spleen (Shortman & Liu 2002). Transduction of plasmacytoid DC, 
macrophages and B cells was also detected (Fig. 3.3B).  
Table  3.3  shows  that,  while  there  was  a  considerable  variation  between 
experiments, the mean percentage of transduction of DCs and macrophages increased 
with time using the GFP LV, while the percentage of transduced B cells decreased. T 
cells were relatively poorly transduced by the LV and almost no transduced T cells 
were present after 30 days. 
The percentage of GFP-expressing cells that could be detected was lower 
when the IiOVA-GFP LV was used (Table. 3.4), although the pattern of transduction 
was similar. In this case, the percentage of transduced cells in most DC subsets and 
macrophages decreased with time, similarly to T and B cells.      84     85     86 
 
 
 
 
Table 3.3.  Percentage of transduced cells
a in the spleen 5 or 30 days after iv 
injection of GFP LV.
          
 
a Percentage of GFP
+ cells after sorting of splenocytes with anti-CD11c microbeads. 
DCs and macrophages were analysed in the CD11c
+ fraction and lymphocytes in the 
CD11c
- fraction. 
b Means ± SD. Control (PBS) vs. treated groups were compared with Mann-Whitney test. 
GFP LV 
% GFP
+ cells  Cell subset 
Day 5
b  p  Day 30
b  p 
MHC II
hi CD11c
hi DCs   1.15 ± 0.56  0.0018  4.01 ± 3.33  0.0042 
CD4
+ CD8
- DCs  2.42 ± 1.60  0.0031  3.49 ± 1.85  0.0041 
CD4
- CD8
- DCs  0.93 ± 0.16  0.0222   2.25 ± 1.44  0.0106 
CD4
- CD8
+ DCs  0.71 ± 0.53  0.0314  1.83 ± 1.49  0.042 
pDCs   2.07 ± 0.55  0.0358  4.27 ± 0.93  0.0358 
Macrophages  7.47 ± 8.12  0.0238  12.69 ± 7.13  0.0238 
B cells  1.03 ± 1.11  0.0046  0.24 ± 0.15  0.0123 
T cells  0.81 ± 0.75  0.0159  0.19 ± 0.08  0.0655      87 
 
 
 
 
 
 
 
Table 3.4.  Percentage of transduced cells
a in the spleen 5 or 30 days after iv 
injection of IiOVA-GFP LV.
          
 
a Percentage of GFP
+ cells after sorting of splenocytes with anti-CD11c microbeads. DCs 
and macrophages were analysed in the CD11c
+ fraction and lymphocytes in the CD11c
- 
fraction. 
b Means ± SD. Control (PBS) vs. treated groups were compared with Mann-Whitney test; 
nd = not determined. 
IiOVA-GFP LV 
% GFP
+ cells  Cell subset 
Day 5
b  p  Day 30
b  p 
MHC II
hi CD11c
hi DCs   0.25 + 0.25  0.0336  0.23 + 0.21  0.0069 
CD4
+ CD8
- DCs  0.64 + 0.75  0.0606  0.25 + 0.19  0.5120 
CD4
- CD8
- DCs  0.25 + 0.20  0.3605  0.40 + 0.06  0.0294 
CD4
- CD8
+ DCs  0.39 + 0.16  0.0195  0.16 + 0.10  0.6012 
pDCs   0.71 + 0.19  0.0178  0.25 + 0.23  0.3539 
Macrophages  1.01 + 1.50  nd  0.63 + 0.01  nd 
B cells  0.24 + 0.11  0.0172  0.07 + 0.05  0.8114 
T cells  0.15 + 0.09  0.1745  0.02 + 0.08  0.2016     88 
3.2.2. LVs transduce dividing DC precursors. 
One of the possible explanations for the persistence of antigen presentation 
after  administration  of  LVs  is  the  transduction  DC  precursors.  To  test  this 
hypothesis, the incorporation of BrdU in transduced DCs was evaluated. BrdU is 
incorporated into dividing DC precursors whose progeny renew the DC population in 
different lymphoid organs (Kamath et al. 2002). To avoid the loss of fluorescence of 
GFP after intranuclear staining of BrdU, the transduced cells were identified by the 
expression  of  the  surface  marker  Thy1.1  (CD90.1)  (Fig.  2.1B).  Thy1  is  a  small 
glycophosphatidylinositol-anchored membrane protein that is expressed in T cells, 
thymocytes  and  nervous  system  in  the  mouse.  It  is  involved  in  cell-to-cell 
interactions both in neural and immunological synapses. Thy1 plays a role in T cell 
activation, although its function in the immune response is not well characterised 
since no ligands or receptors have been identified so far.  Different mouse strains 
selectively express one of two allelic forms of Thy1 (Thy1.1 and Thy1.2) that differ 
in one amino acid in position 89 (arginine in Thy1.1 and glutamine in Thy1.2) (Rege 
& Hagood 2006; Haeryfar & Hoskin 2004). C57BL/6 mice express Thy1.2. Hence, 
in these mice, Thy1.1-expressing cells can be identified with an antibody specific for 
this variant. 
In the first experiment, mice were injected intravenously with a Thy1.1 LV 
(Fig. 2.1B). Then after 48 hours, BrdU was administered intraperitoneally to ensure 
immediate  access  of  the  label  to  dividing  precursors.  BrdU  was  continually 
administered  in  drinking  water  for  ten  days  (to  avoid  toxic  effects  of  long-term 
administration), and then splenocytes were analysed for BrdU incorporation and LV 
transduction. 
Figure 3.4 shows that the majority of splenic DCs and pDCs had proliferated 
after 10 days, as previously reported (Kamath et al. 2002). In contrast only a small 
fraction of splenic macrophages and B cells had divided at this time point. Strikingly, 
a large proportion of transduced DCs and pDCs had divided. LV transduction was 
similar in the BrdU-labelled and BrdU-unlabelled subsets of DCs and higher in the 
BrdU-labelled subset of pDCs (Table 3.5).  BrdU was incorporated at a similar rate     89 
in transduced and non-transduced macrophages. The vast majority of B cells had not 
divided. However, LV transduction was more efficient in the population that had 
incorporated BrdU.  
In a second experiment, BrdU was administered between day 20 and day 30 
after intravenous LV injection. Splenocytes were then analysed on day 30. Consistent 
with the data in table 3.3, there was an increase in the percentage of transduced DCs 
over time. A similar difference between the transduced cells was also observed, with 
the DCs and pDCs having recently proliferated and the macrophages and B cells 
largely remaining non-dividing during this period. These data demonstrate that LVs 
can  transduce  dividing  progenitor  cells  that  give  rise  to  DCs  after  intravenous 
injection. Such transduced progenitors supply DCs in the spleen for at least 30 days 
after LV injection.     90     91  
                                                               
 
 
 
 
Table 3.5.  BrdU incorporation in transduced cells after iv injection of Thy1.1-LV
a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Means + SD. 
b Percentage of Thy1.1
+ among different populations of cells pre-sorted with anti-CD11c microbeads.  Staining for DCs, 
pDCs and macrophages was done in the CD11c
+ fraction; staining for B cells was done in the CD11c
- fraction.  
 
 
 
 
 
BrdU days 2-12  BrdU days 20-30 
 
% 
transduced
b 
% BrdU
+ 
among 
transduced 
% BrdU
+ 
among non 
transduced 
% 
transduced
b 
% BrdU
+ 
among 
transduced 
% BrdU
+ 
among non 
transduced 
DCs  14.86 + 5.68  64.62 + 14.39  55.30 + 15.75  32.55 + 20.56  41.07 + 6.80  39.85 + 8.36 
pDCs  6.30 + 5.39  79.15 + 6.08  39.57 + 5.01  4.29 + 3.31  75.44 + 5.60  24.75 + 1.70 
Macrophages  26.52 + 11.66  7.30 + 4.88  4.78 + 2.67  22.62 + 3.60  10.20 + 0.75  6.96 + 0.84  
B cells  0.79 + 0.43  31.50 + 3.53  6.89 + 1.35  0.30 + 0.34  24.76 + 1.07  4.62 + 0.38 
9
2
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3.3.  Discussion 
In vivo transduction of APCs is crucial for the function of LVs as vaccine 
vectors.  Transduction  of  spleen  DCs  had  been  reported  following  intravenous 
administration of LVs (Palmowski et al. 2004). Here it is shown that in fact, systemic 
LV administration results in sustained transgene expression in all DC subsets and in 
macrophages  for  at  least  30  days.  This  agrees  with  previous  studies  that  show 
persistence of LV integrants and transgene expression in liver and spleen in the long 
term (Esslinger et al. 2003; Pan et al. 2002; VandenDriessche et al. 2002).  
  A smaller proportion of transduced cells was observed when employing a LV 
encoding  OVA.  One  explanation  for  this  could  be  a  lower  expression  of  GFP 
because in the IiOVA-GFP construct its expression is driven by a weaker (UBI). On 
the  other  hand,  OVA  is  a  stronger  immunogen  than  GFP  in  C57BL/6  mice. 
Expression  of  this  molecule  in  APCs  can  lead  to  their  elimination  by  the  CTL 
response  in  a  feedback  mechanism  like  the  one  described  for  infectious  agents 
(Wong & Pamer 2003).  This has also been suggested by the fact that the percentage 
of transduced APCs is higher in immunodeficient than in immunocompetent mice 
(VandenDriessche et al. 2002). It also agrees with the fact that the percentage of 
transduced cells was higher and increased over time when another weak immunogen, 
Thy1.1, was expressed. 
The functional differences among DC subsets are not completely understood. 
It has been suggested that generation of the immune response probably involves the 
simultaneous participation of several DC subtypes (Villadangos & Schnorrer 2007). 
In  this  sense,  genetic  modification  of  the  different  subpopulations  might  be 
important. The majority of transduced DCs are CD4
+ CD8
-, which can be explained 
because  this  subpopulation  of  DCs  is  the  most  abundant  in  the  steady  state, 
accounting for over half of all spleen DCs (Shortman & Liu 2002). Furthermore they 
have a slightly longer half life than CD4
- DCs (Kamath et al. 2000) and are localised 
in the marginal zone of the spleen, which makes them more accessible for the virus 
in the bloodstream (McLellan et al. 2002).  It has been proposed that CD8
+ DCs tend     94 
to polarise a TH1 cell response while CD8
- DCs polarise TH2 responses (Maldonado-
López et al. 1999). However, although the effect of targeting specific DC subtypes 
with LVs remains to be explored, transduction of different DC subtypes with VSV-
G-pseudotyped vectors has been reported to generate both CD4
+ and CD8
+ T cell 
responses and efficient immunisation with LVs (Dullaers et al. 2006; Loisel-Meyer 
et al. 2009; Rowe et al. 2006).  
LVs  also  transduce  pDCs,  whose  antigen-presenting  function  is  more 
controversial.  However,  it  has  been  shown  that  these  cells  are  important  in  the 
initiation  of  innate  anti-viral  responses  (Brown  et  al.  2007)  and  have  become  a 
potential target for vaccination. 
  Transduction  of  macrophages  and  B  cells  probably  participate  in  T  cell 
priming  following  immunisation  with  LVs.    It  is  known  that  macrophages  are 
effective stimulators of memory T cells, although not so effective as primers of naïve 
T cells  (Macatonia et al. 1992).  B cells can induce both effector or regulatory T cell 
differentiation and expansion (Chen & Jensen 2008).  However,  LVs  targeted to 
specifically transduce DCs still generate an effective immune response despite a poor 
transduction of other APCs (Lopes et al. 2008; Yang et al. 2008). 
Interestingly, transduced DCs were still present 30 days later even when their 
lifespan is known to be limited to ~2-3 days in the case of cDCs, ~14 days in pDCs  
or even shorter after they are activated (Kamath et al. 2002; O' Keeffe et al. 2002). 
Indeed,  the  percentage  of  GFP
+  cells  increased  over  time  in  all  DC  subsets  and 
macrophages, but not in T cells and B cells. This contrasts with other studies that 
have shown a decrease in transgene expression (Kimura et al. 2007) or in the number 
of LV integrants (Pan et al. 2002) in the spleen over time. However, these studies 
have not specifically addressed transgene expression in DCs. 
It  was  hypothesised  that  a  reason  for  this  could  be  the  transduction  of 
proliferating cells that give rise to a long term supply of genetically-modified DCs in 
the spleen. The fact that DCs are the only predominantly BrdU-labelled, transduced 
population  argues  for  the  transduction  of  a  committed  DC  progenitor  that  has 
diverged from common progenitors of macrophages and lymphocytes. Macrophages 
instead are long-lived, non-dividing cells (Wijffels et al. 1994), as reflected by the     95 
absence of BrdU incorporation (Fig. 3.4). Their long life span  could explain the 
persistence of transgene expression in this cell population.  
DC precursors are present in the bone marrow (Kang Liu et al. 2009) but also 
locally in the spleen (Naik et al. 2006). Long-term DC precursor transduction in the 
spleen is only observed after intravenous but not after subcutaneous injection. Bone 
marrow precursors could also be transduced after subcutaneous injection and give 
rise to transduced DCs in other lymphoid tissues, but this has not been observed 
(Rowe et al. 2006). Furthermore, the fact that other lineages like lymphocytes or 
macrophages do not incorporate BrdU argue for the transduction of a committed 
local progenitor in the spleen more than an earlier progenitor in the bone marrow.  
Against this argument is the fact that pDCs also incorporate BrdU. No local 
precursor  of  these  cells  has  been  identified  in  peripheral  tissues,  although  this 
remains a possibility.  It is generally accepted that pDCs originate from the bone 
marrow, enter the bloodstream and are distributed to all lymphoid organs. They also 
have a longer life span than cDCs (Liu et al. 2009; O' Keeffe et al. 2002).  Therefore, 
incorporation  of  BrdU  in  transduced  pDCs  can  only  be  explained  either  by 
transduction of a precursor in the bone marrow, a not yet identified local precursor in 
the spleen or that, being precursors themselves, LV transduction induces activation 
and proliferation of these cells. 
The presence of divided transduced cells at least 30 days after LV injection 
suggests either that the splenic DC precursors proliferate for up to 30 days after 
transduction,  or  that  transduced,  dormant  precursors  are  activated  to  proliferate 
throughout  this period. Part of the BrdU incorporation might also come from the 
clonal expansion of cDCs themselves, as recent evidence shows that DCs are not 
necessarily  end  cells  as  generally  assumed,  but  retain  some  capacity  for  further 
division (Kabashima et al. 2005; Zhang et al. 2004; Diao et al. 2007).  
To confirm transduction of DC precursors, transfer of transduced splenocytes 
from mice injected with LVs to naïve mice was attempted. However, it was not 
possible to identify a transduced progeny of DCs in purified CD11
+ cells from the 
recipients’ spleens.  This can be attributed to their low number and to the purification 
techniques that were employed. It is thus necessary to validate this hypothesis with 
further experiments, including reconstitution of bone marrow or precursor assays in     96 
irradiated  and  non-irradiated  mice,  as  well  as  ex  vivo  transduction  of  purified 
precursors with LVs.  
In  conclusion,  these  results  suggest  that  transduction  of  proliferating  DC 
precursors can give rise to long term supply of these cells in the spleen, allowing a 
sustained, potentially life-long, transgene expression. This is relevant considering the 
current interest in using LVs as vaccine vectors or as genetic immunomodulators.    97 
 
CHAPTER 4 
4. PERSISTENCE OF ANTIGEN PRESENTATION 
AFTER ADMINISTRATION OF LENTIVIRAL 
VECTORS 
4.1.  Introduction 
The persistence of transgene expression in DCs calls into question whether 
LV transduction of these cells results in durable antigen processing and presentation. 
The consequences of persistent antigen presentation have been previously addressed 
in  various  models,  but  they  are  still  not  fully  understood.  Although  antigen 
presentation  for  several  months  is  beyond  the  time  frame  of  an  optimal  primary 
immune response, it has also been proposed that persistence of antigen is important 
for the vaccine function of some vectors including adenovirus (Tatsis et al. 2007), 
VSV (Simon et al. 2007)  and LVs (He et al. 2005; Kimura et al. 2007). 
4.1.1. Regulation of the longevity of antigen presentation 
The  induction  of  CTL  responses  is  a  complex  process  triggered  by  the 
encounter of antigen presented in APCs and cognate T cells. This can result in full 
activation  of  the  T  cell,  with  acquisition  of  effector  functions  and  generation  of 
memory, or in tolerance due to clonal anergy or deletion.  The balance between these 
rather  opposite  outcomes  depends  on  the  conditions  in  which  the  antigen  is 
encountered. Several factors, including the activation status of the APC, presence of 
cytokines,  antigen  distribution,  localisation  and  amount,  as  well  as  duration  of 
antigen  presentation,  play  an  important  role  in  defining  the  fate  of  the  cell 
(Lanzavecchia & Sallusto 2000; den Boer et al. 2001).     98 
In  general,  the  time  during  which  antigen  is  presented  throughout  a  CTL 
response is limited by several mechanisms. Firstly, the MHC-I/peptide complexes 
have a short half life (~10 hours). The maintenance of antigen presentation depends 
on the continuous synthesis and antigen loading of MHC-I (Lanzavecchia & Sallusto 
2000).  Rapid  clearance  of  MHC-I/peptide  complexes  might  explain  why  CTL 
priming  is  impaired  when  antigen  supply  is  restricted  to  short  periods  of  time 
(Ludewig et al. 2001). 
Antigen presentation is also limited by the life span of activated APCs. In the 
case  of  DCs,  stimulation  of  TLRs  induces  accumulation  of  pro-apoptotic  factors 
(Hou  &  Van  Parijs  2004).  Signalling  through  other  receptors  results  in  nuclear 
translocation of NFAT  (Zanoni et al. 2009). These two events result in cell death. 
Activated T cells also deliver pro- and anti-death signals to DCs during the CTL 
response. CD8
+ T cells eliminate DCs via secretion of cytolytic granules (Yang et al. 
2006), while CD4
+ T cells induce DC apoptosis via extrinsic and intrinsic pathways 
(Matsue et al. 1999; Pradhan et al. 2006; Wang et al. 1999). In addition, CD4
+ T 
cells  can  also  protect  DCs  from  CTL-mediated  elimination  and  prolong  class  I-
restricted  antigen  presentation  by  engagement  of  RANK  and  CD40  (Chen  et  al. 
2004; Mueller et al. 2006). 
The balance between the mechanisms that prolong or limit the longevity of 
activated DCs is necessary for optimal CD8
+ T cell priming and to prevent aberrant 
T cell activation and autoimmunity.  This is emphasised by the fact that extension of 
the life span of DCs can result in autoimmunity (Chen et al. 2006) and abnormal 
accumulation  of  antigen-specific  CD8
+  T  cells  in  lymphoid  organs,  which  is 
associated with pathology (Pradhan et al. 2006; Ronchese & Hermans 2001). 
4.1.2. Effects of persistent antigen presentation on the CTL response 
A relatively short-term exposure to peptide/MHC-I complexes is all that is 
required for commitment of CD8
+ T cells to expansion and differentiation.  In vitro, 
this initial stimulus can be as short as 2 hours (van Stipdonk et al. 2001; Wong &  
Pamer 2001). Nevertheless, a concerted ‘3 signal’ stimulus for at least 24-40 hours is 
required for optimal clonal expansion and acquisition of function (Curtsinger et al.     99 
2003). This is consistent with in vivo data showing that in some acute infections, 
antigen presentation is limited to ~24-36 hours, after which the immune response 
carries on independently (Wong & Pamer 2003; Norbury et al. 2002; Williams & 
Bevan  2004).  Curtailing  the  duration  of  antigen  presentation  can  attenuate  the 
magnitude  of  the  primary  CTL  response  (Prlic  et  al.  2006;  Stock  et  al.  2004). 
However, in some cases it has no effect, probably because of other factors such as 
ongoing inflammation (Mercado et al. 2000; Williams & Bevan 2004).   
When antigen presentation persists after the initial stimulation period, it can 
further modulate—if not determine—the CTL response. This has been extensively 
studied  in  chronic  bacterial  and  viral  infections.  Persistent  antigen  presentation 
results  in  continuous  recruitment  of  naïve  CD8
+  T  cells  in  chronic  lymphocytic 
choriomeningitis virus (LCMV) and polyoma virus infections (Vezys et al. 2006). 
Similarly,  persistence  of  antigen  in  cytomegalovirus  (CMV)  infection  drives 
differentiation of CD8
+ T cells and accumulation of memory cells that are functional, 
albeit  not  showing  a  completely  activated  phenotype  (Snyder  et  al.  2008). 
Furthermore, naïve cells primed later in the immune response by ongoing antigen can 
differentiate into memory CD8
+ T cells (Turner et al. 2007).    
However, antigen persistence can also result in exhaustion or induce T cell 
death due to continuous TCR triggering (Bucks et al. 2009; Mueller & Ahmed 2009; 
Wherry et al. 2003; Zajac et al. 1998). This has been related with the amount and 
distribution  of  the  antigen.  For  example,  LCMV  strains  that  spread  rapidly  and 
systemically lead to a phase of strong CD8
+ T cell proliferation followed by clonal 
exhaustion, while strains that replicate slowly and spread less induce long-lasting 
CTL  memory  (Moskophidis  et  al.  1993).  In  general,  antigen  that  is  present 
systemically and in high amount is more likely to result in CD8
+ T cell disfunction, 
especially when it is presented by non-professional or immature APCs.   Instead, 
localised  antigen  presentation,  in  lower  amounts  and  in  an  environment  of  APC 
activation promotes a stronger CTL response (Zinkernagel & Hengartner 2004).  
Although most of these studies refer to the priming of naïve CD8
+ T cells, the 
effect of antigen on memory CD8
+ T cells might be different. These cells are less 
dependent  on  antigen  exposure  and  co-stimulation  (Iezzi  et  al.  1998).  The 
dependence of CD8
+ T memory cells on antigen presentation is controversial. It has     100 
been reported that maintenance of these cells can be either antigen-dependent (Oehen 
et al. 1992; Kündig et al. 1996; Gray & Matzinger 1991) or independent (Müllbacher 
1994; Lau et al. 1994; Bruno et al. 1995). 
The longevity of antigen presentation can also modulate the CTL response 
through its effect on helper T cells.  In contrast with CD8
+ T cells, CD4
+ T cells 
require  antigen  stimulation  throughout  their  expansion  phase  (Obst  et  al.  2005a; 
Williams & Bevan 2004). It has been shown that prolonged antigen stimulation of 
CD4
+ T cells promotes their proliferation and activation even in the absence of DC 
maturation  (Obst  et  al.  2007).  Consequently,  durable  antigen  presentation  is 
necessary for an optimal CD4
+ T cell response, which is important for the generation 
of optimal primary CTL responses and CD8
+ T cell memory. 
4.1.3. Persistent antigen presentation and vaccination 
It has been proposed that persistence of antigen is important for the function 
of vaccines that aim to protect through  cell-mediated immunity  (He et al. 2006; 
Simon et al. 2007; Tatsis et al. 2007). The mechanism is not clear since the role of 
different CD8
+ T cell populations (effector, effector memory and central memory) in 
providing protection remains controversial.   
Some  vaccine  vectors,  such  as  those  derived  from  adenovirus,  have  been 
shown to persist and continue to produce antigen. This contributes to maintaining a 
cohort  of  activated  effector  and  memory  effector  T  cells  (Tatsis  et  al.  2007).  
However, it has been argued that these cells have an impaired response. CD8
+ T cells 
undergoing  protracted  antigen  stimulation  show  a  partially  exhausted  phenotype 
(Yang et al. 2006) and the early termination of antigen expression seems to generate 
a more robust secondary response (Finn et al. 2009). A similar observation has been 
reported following immunisation with persistent DNA vectors.  Although durable 
antigen expression maintains a bigger pool of cognate CD8
+ T cells, a transient burst 
of antigen results in a better secondary response (Hovav et al. 2007; Radcliffe et al. 
2007).  
Part of the efficiency of LVs as vaccine vectors has been attributed to their 
ability  to  display  a  more  durable  antigen  presentation  than  other  vaccination     101 
strategies, e.g., better than peptide pulsed DCs  (He et al. 2005).  However, the 
duration  of  antigen  presentation  and  the  consequences  of  the  role  of  long-term 
transgene expression in DCs have not yet been assessed in the context of LVs.  
4.1.4. Aims 
·  Measure the duration of antigen presentation following LV in vivo transduction 
of professional APCs.  
 
·  Determine the effect of protracted antigen presentation on cognate T cells. 
 
·  Compare the effects of LVs on the activation status of transduced DCs in the 
short and the long term. 
 
·  Examine the consequences of sustained antigen presentation on the long-term 
outcome of immunisation with LVs. 
4.2.  Results 
4.2.1. Persistence of Ag presentation in spleen after immunisation 
with LVs.  
To  test  whether  persistence  of  transduced  APCs  in  the  spleen  resulted  in 
durable  antigen  presentation,  proliferation  of  adoptively  transferred  lymphocytes 
from TCR-transgenic OT-1 mice was measured. These cells specifically recognise 
the  CD8  epitope  OVA257-264  (SIINFEKL)  in  the  context  of  H2K
b.  Prior  to  their 
transfer  into  naïve  or  immunised  mice,  the  cells  were  labelled  with 
carboxyfluorescein succinimidyl ester (CFSE) to monitor their expansion, and then 
detected  by  FACS  in  the  spleen  5  days  after  transferred  (Fig.  1).  LVs  were 
administered intravenously to keep consistent with the previous experiments. 
When  transferred  five  days  after  immunisation,  almost  all  the  OT-1  cells 
underwent division, resulting in an increase in their absolute number (Fig. 4.1A).     102 
Complete dilution of CFSE in most of the cells denotes that they underwent at least 
7-8  divisions.  Interestingly,  OT-1  cells  transferred  one  month  after  mice  were 
immunised also proliferated. Antigen presentation could be detected even 2 and 3 
months after immunisation (Fig. 4.1A). However, the percentage of divided cells and 
the number of divisions they underwent progressively decreased in the later time 
points (Fig. 4.1B).  Proliferation of OT-1 cells was not observed in the long term 
when mice were injected iv with OVA257-264 plus monophosphoryl lipid A adjuvant 
or  a  vector  encoding  an  irrelevant  antigen  (GFP  LV)  (Fig.  4.1C).  In  summary, 
antigen presentation is sustained for at least 3 months after systemic administration 
of lentivectors, leading to proliferation of cognate CD8
+ T cells. 
4.2.2. Role of the spleen in long-term antigen presentation 
To determine the site of prolonged antigen presentation, experiments were 
repeated in splenectomised mice and OT-1 cell expansion measured in peripheral 
blood by FACS 5 days after adoptive transfer. As shown in figure 4.2, almost all of 
the OT-1 cells divided in the mice that were immunised 5 days before OT-1 transfer 
and removal of the spleen did not affect the number of cells that proliferated. This 
indicates that following intravenous injection of  LVs, antigen presentation in the 
short term takes place in anatomical sites other than the spleen. In contrast, in the 
mice  transferred  with  OT-1  cells  30  days  after  immunisation,  there  was  an 
approximately 50% reduction in the percentage of OT-1 cells that proliferated when 
the spleen was removed (Fig. 4.2).  It is unlikely  that this difference is due to a 
homing problem of the transferred cells in the absence of spleen, as no differences 
were observed in the proliferation levels in mice injected after splenectomy (data not 
shown).  
This  means  that  the  spleen  plays  a  significant  role  in  long-term  antigen 
presentation in LV-immunised mice, although it is not the exclusive anatomical site 
where it takes place. Antigen is also presented by cells in other tissues or organs both 
in the short and the long term.   
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4.2.3. Activation of transferred OT-1 cells 
In  order  to  examine  the  activation  status  of  the  transferred  OT-1  cells, 
expression  of  the  activation  marker  CD44  and  IFN-￿  production  in  response  to 
OVA257-264  re-stimulation  were  measured.  Figure  4.3A  shows  that  CD44  was 
upregulated in the V￿2
+ V￿5.1, 5.2
+ cell population that contained the transferred 
OT-1 cells. More activated cells were observed when the OT-1 cells were transferred 
5 days after immunisation, but a significant population of activated cells was also 
detected when transfer was delayed until day 30. In the immunized mice with no OT-
1 cells transferred, an average of approximately 200 spots/10
6 cells was observed, 
which decreased to 100 spots/10
6 cells after 30 days (Fig. 4.3B), corresponding to a 
long-lived endogenous CD8
+ T cell response. Upon OT-1 adoptive transfer, these 
numbers increased to 950 and 250 respectively, showing that the transferred cells 
were also functionally activated. 
4.2.4. Reverse transcription is necessary for long term antigen 
presentation 
  Previous  studies  have  shown  that  proteins  can  be  co-purified  with 
concentrated  retroviral  vectors  pseudotyped  with  VSV-G  envelope,  leading  to 
pseudotransduction by protein instead of gene expression (Gallardo et al. 1997; Liu 
et al. 1996). To demonstrate that reverse transcription is necessary for short- and 
long-term antigen presentation, a control was performed using a packaging plasmid 
with two mutations (D185A and D186A) in the highly conserved YMDD motif of 
the catalytic core of the reverse transcriptase (Kaushik et al. 1996; Lowe et al. 1991).  
LVs produced with this plasmid (RTmut) contain all the components of the viral 
particle, but are unable to reverse transcribe the viral RNA because the packaged RT 
is not functional.   
RTmut/LVs were titrated by p24 quantification and tested in vitro using GFP 
as a reporter gene.  Low expression of GFP was observed in 293T cells transduced 
with  a  high  concentration  of  GFP/RTmut  LV  (Fig.  4.4A),  though  not  at  low     107 
multiplicity  of  infection.  To  determine  if  reverse  transcription  is  necessary  for 
sustained in vivo antigen presentation, mice were injected with IiOVA-GFP/RTmut 
LV and the immune response was measured by ELISpot and OT-1 cell transfer. 
Figure 4.4B shows that no IFN-￿-producing OVA-specific T cells were measurable 
by ELISpot. However, a small number of OT-1 cells proliferated in mice injected 
with  IiOVA-GFP/RTmut  5  days  earlier,  but  not  when  transferred  30  days  after 
immunisation.  This means that in the absence of reverse transcription, there is a 
minor immune activation that could be explained either by co-purified protein. It has 
also been described the existence of low and transient expression of the transgene by 
directly from the viral RNA of retroviral vectors (Galla et al. 2004) which could also 
be  playing  a  role  in  lentiviral  transduction.  However,  for  effective  antigen 
presentation and long-term expression, reverse transcription is necessary. 
4.2.5. In vivo DC activation 
To  compare  activation  status  of  DCs  following  LV  administration,  the 
expression  of  different  co-stimulatory  molecules  was  analysed  in  these  cells  in 
treated and control mice.  In these experiments, transduced cells were detected by the 
expression of the membrane protein Thy1.1 encoded by a LV, and staining with an 
anti-Thy1.1 antibody. Activation status was assessed at an earlier time point than in 
previous experiments (day 3 instead of day 5) since some activation markers can be 
quickly downregulated. 
As shown in figure 4.5, CD40, CD80 and CD86 were upregulated in the 
transduced DCs of mice injected 3 days before.  However, the levels of expression 
30 days after administration of LVs were at the same level than in control mice 
injected with PBS (Fig. 4.5B). These results suggest that direct administration of LVs 
induces DC maturation. However, the transduced cells that persist in the spleen in the 
long term show a basal expression of co-stimulatory molecules, suggesting they are 
in an immature state.  
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4.2.6. Persistent cytolytic activity after a single injection of LVs 
Finally, cytolytic activity was examined in the mice that had been treated 
with intravenous LVs. Figure 4.6 shows that OVA257-264–pulsed targets, injected into 
mice 10 weeks after  LV immunisation were lysed overnight. The efficiency was 
lower than that observed 10 days after LV administration, but the difference was not 
statistically  significant.  This  is  consistent  with  previous  reports  in  which  mice 
injected  intravenously  with  LV  had  a  strong  T  cell  memory  response  when 
challenged  one  year  later  (Rowe  et  al.  2006
a).  Together  these  data  show  that 
following intravenous administration of LV there is a protective memory CD8
+ T 
cell response.   
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4.3.  Discussion 
  The data presented here demonstrate that administration of LVs results in 
long-term antigen presentation to CD8
+ T cells for at least 90 days. This agrees with 
the persistence of transgene expression in DCs and macrophages shown in chapter 3 
and reported in other studies (Kimura et al. 2007; VandenDriessche et al. 2002).  
This challenges the concept of antigen presentation as a process restricted in time by 
the  short  half  life  of  activated  DCs  and  the  elimination  of  antigen-bearing  DCs 
during the CTL response. Indeed, the latter might be the explanation for the low 
percentage of transduced DCs observed after administration of OVA-encoding LVs 
and the reduction in the percentage of proliferated cognate T cells transferred 30 or 
more days after immunisation (Table 3.4).  
The persistence of antigen presentation could be due to a continuous supply 
of transduced DCs derived from dividing precursors, which could counterbalance 
their  elimination  and  maintain  a  population  of  antigen-expressing  cells.  DC 
precursors  could  act  as  a  reservoir  of  antigen  that  is  not  accessible  to  CTL 
elimination and prolong antigen presentation after mature DCs die or are eliminated.  
The spleen could be the source of these precursors (Naik et al. 2006), since long-
term antigen presentation was impaired when the spleen was removed, but more 
experimental work is necessary to prove this hypothesis. 
The possibility of antigen presentation by other long-lived cells, including 
macrophages  or  non-professional  APCs,  cannot  be  discarded.  LV-transduced 
macrophages persist in the spleen of injected mice (Table 3.3); these cells are also 
competent  in  stimulating  naïve  CD8
+  T  cells  to  proliferate  and  differentiate  into 
memory  T  cells  (Pozzi et  al.  2005).  CD4
+  T  cells  could  also  play  a  role  in  the 
maintenance of long-term antigen presentation by protecting antigen-bearing DCs 
from elimination by CTLs (Mueller et al. 2006). 
The transduction of a DC precursor would not necessarily result in effective 
T cell stimulation by its progeny, as they might not be activated. Furthermore, it is 
expected that the activation signals delivered by the LV (e.g., viral RNA, DNA from     114 
reverse transcription, components of the viral preparation) will decrease with time.  
In fact, it was observed that expression of most co-stimulatory molecules that are 
initially upregulated in DCs following LV transduction return to basal levels after 30 
days.  
It is widely accepted that antigen presentation by resting DCs can induce 
peripheral CD8
+ T cell tolerance (Bonifaz et al. 2002; Probst et al. 2003). However, 
here it was observed that protracted antigen presentation induced proliferation and 
activation of adoptively transferred OT-1 T cells, as demonstrated by upregulation of 
CD44 and secretion of IFN-￿. Residual costimulatory activity of DCs could be an 
explanation for this (Fig. 4.5), although these results must be interpreted carefully. It 
has been shown that production of other cytokines by CD8
+ T cells (e.g., IL-2, TNF-
￿) can be impaired in the absence of adequate co-stimulation in spite of normal IFN-
￿ production (Wherry et al. 2003; Zajac et al. 1998). 
It has been argued in other models that prolonged antigen presentation could 
hinder the immune response. Some recent studies have also associated persistence of 
antigen with impaired secondary responses (Finn et al. 2009; Hovav et al. 2007; 
Radcliffe  et  al.  2007).    Results  vary  depending  on  the  model  studied  since  the 
outcome  of  the  immune  response  depends  on  other  factors,  such  as  antigen 
distribution  and  amount,  inflammatory  stimulus  and  the  type  of  cell  presenting 
antigen (Storni et al. 2003).   
Here  it  was  observed  that  LVs  induce  potent  primary  and  memory  CTL 
responses. A single injection of LVs was sufficient to provide protective immunity 
10 weeks later, confirming  results obtained previously (Rowe et al. 2006).  The 
persistence of antigen can be playing a role in this end result by maintaining a bigger 
pool  of  cognate  CD8
+  T  cells  through  priming  of  naïve  cells  (demonstrated  by 
priming of OT-1 cells) or of memory cells, which require less co-stimulation or are 
more  amenable  for  boosting  (Vezys  et  al.  2006).  Furthermore,  sustained  TCR 
stimulation is important for priming of CD4
+ T cells (Obst et al. 2005; Obst et al. 
2007), which are critical for the CTL response induced by LVs (Dullaers et al. 2006; 
Rowe et al. 2006).   
To  further  characterise  the  immune  consequences  of  persistent  transduced 
DCs as well as other APCs, it would be important to identify their effect on different     115 
subpopulations of T cells. This was attempted through ex vivo antigen presentation 
assays and transfer of transduced  cells from vaccinated to naïve mice. However, 
purification  of  these  cells  proved  to  be  difficult  due  to  the  low  frequency  of 
transduced cells. Besides, the purification technique that was employed (antibody 
labelling and magnetic bead separation) and the disruption of the spleen architecture 
may affect the ability of transduced DCs to present antigen.  
Viral particles void of reverse transcriptase activity were used as controls in 
these experiments. Surprisingly, some immune response was observed when using 
adoptive OT-1 transfer. Although this can be due to protein co-purification in the 
concentrated  virus,  it  has  also  been  reported  that  direct  translation  of 
gammaretroviral RNA can result in low and transient expression of the transgene 
(Galla et al. 2004). This has not been studied in lentiviruses and its immunological 
consequences remain to be explored. 
In  conclusion, it has been shown that  LVs can transduce  and persistently 
express antigen within DC. Furthermore, these DCs are still functional, in being able 
to  induce  proliferation  and  activate  T  cells.  This  contributes  to  the  protective 
immunity generated by these vectors.     116 
CHAPTER 5 
5. REGULATION OF ANTIGEN EXPRESSION WITH 
LENTIVIRAL VECTORS 
5.1.  Introduction 
  The regulation of transgene expression has been a major challenge in gene 
therapy.  For  therapeutic  genes,  modulating  their  expression  would  avoid  the 
occurrence  of  toxicity  by  overexpression  (Stieger  et  al.  2009).  In  the  context  of 
antigen genes, it would allow turning ‘off’ the gene when the therapeutic effect is 
achieved,  and switching it back ‘on’ if needed. A regulatable antigen  expression 
model would also be an important tool for basic immunological research and to test 
the following hypotheses: 
(1) A conditional system of antigen expression would help to understand the 
dynamics of T cell priming induced by LVs. It is still not clear how does the duration 
of antigen presentation affect the magnitude of the primary response and whether the 
presence of antigen is important for the maintenance of CD8
+ T cell memory. Using 
vaccine vectors with inducible antigen expression systems, Radcliffe et al. (2007) 
and Finn et al. (2009) showed that a prolonged antigen presentation resulted in a 
bigger pool of cognate T cells, but the secondary responses were better when priming 
was  restricted  to  shorter  periods  of  time.    These  conclusions  were  based  in 
immunisations with a DNA and an adenoviral vector, respectively, both of which 
lead to long-term expression of the antigen. The outcome could be different with 
LVs,  since  a  persistent  supply  of  antigen-expressing  DCs  can  be  maintained  by 
transduction of dividing precursors. A more detailed study of the consequences of 
duration  of  antigen  presentation  may  be  achieved  with  a  regulatable  antigen 
expression system in these vectors. 
(2) This model would also allow segregating the stimulation of the innate 
immune  response  from  the  actual  expression  of  the  antigen.  Using  an  inducible     117 
antigen expression system in transgenic mice, Probst et al. (2003) demonstrated that 
induction  of  antigen  presentation  without  any  further  stimulus  resulted  in  a 
tolerogenic response that could not be broken by subsequent administration of the 
antigen and adjuvants.  In contrast, when accompanied by a stimulatory signal (anti-
CD40), it resulted in protective immunity. It has been proposed that the lentiviral 
particle and other components in the LV preparations activate DCs, contributing to 
the  generation  of  an  immune  response  to  the  transgene.    The  effects  of  these 
components could be studied in more detail if the expression of the antigen were 
segregated from the initial inflammatory signal. In this way, antigen expression could 
be delayed and induced peripherally with or without different stimulatory signals to 
study their effects. 
  (3) The kinetics of precursor transduction could also be further analysed with 
a  regulatable  system.  Dividing  DC  precursors  may  be  responsible  for  the 
maintenance of transduced DCs in the long term. Antigen-expressing DCs are also 
eliminated by the CTL response. Therefore, delaying the expression of the antigen 
could result in a larger accumulation of transduced DCs, deriving from a reservoir of 
transduced precursors. This could result in a stronger immune response when the 
antigen expression is switched ‘on’. 
  (4)  This  model  could  address  whether  persistence  of  transcription  is 
necessary for sustained antigen presentation and not the result of pseudotransduction. 
The first is supported by the fact that the CD8
+ T cell response is curtailed when 
reverse transcription is absent (Fig. 4.4), but could be confirmed by controlling the 
duration of antigen expression. 
  There are currently several systems of regulatable gene expression, some of 
which have been used with LVs.   
5.1.1. Ligand-dependent regulatable systems 
  The  systems  for  exogenous  modulation  of  gene  expression  have  three 
components: (1) a regulatable promoter that drives the expression of the gene of 
interest, (2) a regulatory protein that stimulates or inhibits this promoter and (3) a     118 
ligand that modulates binding of the regulatory protein to the promoter, usually by 
induction of conformational changes and polymerisation.  
Four drug-dependent systems have been used in vivo and their components 
are described in Table 5.1.  The tetraycycline-regulatable system has been the best 
characterised and extensively tested in the context of different vectors. It is regulated 
by  tetracycline  (Tet)  or  its  analogue,  doxycycline  (Dox).  Both  drugs  have  a 
favourable pharmacologic profile for in vivo usage (Stieger et al. 2009).      119 
 
Table 5.1. Regulatable gene-expression systems. 
 
a The rapamycin-dependent transactivator is a heterodimer formed by two units that bind in 
the  presence  of  rapamycin:  FRB/p65-HSF1  (fusion  of  a  portion  of  FKBP-rapamycin 
complex binding domain and activation domains from p65 subunit of NF￿B and human heat 
shock  factor  1)  and  ZFHD1/3X  FKBP  (DNA  binding  domain  derived  from  human 
transcription factors Zif268 and Oct-1 and 3 copies of FKBP rapamycin-binding protein). 
b “Switch” is a fusion protein of GAL4 DNA binding domain from S. cerevisiae, a truncated 
binding  domain  of  human  progesterone  receptor  and  the  activation  domain  of  the  p65 
subunit of human NF￿B 
cIn the absence of tamoxifen, Cre recombinase is associated with heat shock proteins and is 
cytoplasmatic.  After association with tamoxifen, Cre traslocates to the nucleus, excises a 
loxP-flanked ‘stop’ cassette and induces gene expression. 
d VgEcR consists of VP16 transactivation domain from herpes simplex virus fused with a 
mutated ecdysone receptor of Drosophila. 
Abbreviations: GAL4 UAS = galactose-induced regulator 4 upstream activation sequence; 
TKmin = minimal thymidine kinase promoter from herpes simplex virus; RXR = retinoid X 
receptor; E/GRE = ecdysone/glucocorticoid response elements; 
HSPmin = minimal heat shock protein promoter.  The rest of the abbreviations are explained 
elsewhere in the text. 
System  Ligand  Regulatory 
protein 
Regulatable 
promoter  Ref. 
Tetracycline-
dependent 
Tetracycline 
or 
doxycycline 
tTA (TetOff) 
rtTA (TetOn) 
KRAB-TetOn 
rtTA/KRAB 
 
7X TetR binding sites 
linked to CMVmin 
See text 
Rapamycin-
dependent 
Rapamycin  Rapamycin-
dependent 
transactivator
a 
12X ZFHD1 binding 
sites linked to 
CMVmin 
Rivera et al. 
1996 
Mammalian 
steroid 
receptor 
Mifepristone 
 
 
 
Tamoxifen 
 
“Switch” 
protein
b 
 
 
Mutant 
oestrogen 
receptor fused 
with Cre
c 
4X GAL4 UAS 
binding sites linked 
to TKmin  
 
 
 
 
 
Wang et al. 
1994 
 
 
 
Feil et al. 
1997 
Insect 
steroid 
receptor 
Ecdysteroids 
(e.g., 
muristerone) 
Heterodimer 
formed by 
VgEcR
d and 
RXR 
5X E/GRE binding 
sites linked to HSPmin 
 
No et al. 
1996     120 
5.1.1.1.  Tetracycline-regulatable system 
  This  system  is  based  on  the  E.  coli  Tn10  resistance  operon,  which  is 
composed of the Tet repressor protein (TetR) and a DNA regulatory sequence called 
the Tet operator (TetO). In the absence of Tet or Dox, the TetR protein binds to the 
TetO and represses transcription; the process is reverted by the presence of Tet or 
Dox (Hillen et al. 1982). 
  Five different Tet-responsive regulatory systems have been developed based 
on the bacterial operon, shown in figure 5.1 (Stieger et al. 2009).   
5.1.1.1.1.  TetOff 
  In  this  system,  transcription  is  regulated  by  tTA  (Tet-controlled 
transcriptional  activator),  a  chimeric  protein  composed  by  TetR  fused  to  the 
transactivator VP16 of herpes simplex virus. Expression of the gene of interest is 
under  control  of  a  promoter  that  consists  of  seven  repeats  of  the  TetO  DNA 
sequence—also referred as Tet-responsive element (TRE)—and the minimal CMV 
promoter  (CMVmin).  In  the  absence  of  Dox,  tTA  binds  to  TRE  and  activates 
transcription.  Dox  induces  conformational  changes  in  tTA,  which  detaches  from 
TRE and gene expression is silenced. 
5.1.1.1.2.  TetOn 
  Four  point  mutations  in  the  TetR  domain  of  tTA  result  in  a  reverse  Tet 
repressor (rtTA) that exerts the opposite effect of tTA, i.e., it binds to TRE and 
induces gene expression in the presence of Dox. Improved versions of rtTA (rtTA2
S-
M2 and rtTA
S-S2) have been generated by mutagenesis and codon optimisation in 
order to improve the sensitivity to Dox and reduce background activity (Urlinger et 
al. 2000). 
5.1.1.1.3.  KRAB-TetOn 
This  system  is  based  on  a  protein  formed  by  the  fusion  of  TetR  with  a 
transinhibitor protein called Krüppel-associated box (KRAB), which is part of the     121 
zink finger protein Kox1 in humans or Kid-1 in mice. The KRAB domain inhibits 
RNA polymerases  II  and  III within a range of 3 kb of its DNA attachment site 
(Margolin et al. 1994). Detachment of KRAB from the promoter and induction of 
gene expression is dependent on the presence of Dox. 
5.1.1.1.4.  Combined TetOn/TetOff  
  Alternatively,  a  combination  of  the  systems  described  before  has  been 
developed in order to reduce background expression. rtTA-VP16 and KRAB can be 
combined in a single cassette separated by an internal ribosomal entry site (IRES). In 
this system, expression is induced by the presence of Dox (Freundlieb et al. 1999). In 
other  cases,  the  gene  of  interest  can  be  under  control  of  a  separate  constitutive 
promoter, which is inhibited by the presence of KRAB (Szulc et al. 2006). Although 
the  background  expression  is  reduced,  the  size  of  the  coding  cassette  and  the 
immunogenicity of these molecules restrict the application of this system. 
5.1.1.1.5.  Autoregulatory loop TetOn/TetOff 
  Another alternative used to minimise the background expression is the use of 
a system with an autoregulatory loop, in which the both transactivator and the gene 
of interest are expressed under control of the Tet-inducible promoter. In this case, 
expression of the transactivator only takes place in the presence of Dox. This reduces 
the  toxicity  of  the  transactivator  and  the  background  expression,  although  the 
induction of expression may take longer (Haberman et al. 1998).  This design can 
also be used with a TetOff mechanism.  
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5.1.1.2.  Regulatable expression systems in lentivectors 
  Most of the conditional expression systems mentioned above have been used 
in  expression  plasmids.  Some  have  also  been  incorporated  into  viral  vectors, 
especially adenovirus-derived vectors (Lee et al. 2005).  The main limitations have 
been background expression, restriction in the use of single vectors because of the 
size  of  the  regulatory  proteins  and,  in  some  cases,  reduction  of  the  viral  titers. 
Immune responses against the proteins involved in transgene regulation have also 
been reported in non-human primates, particularly with TetOn systems (Le  Guiner et 
al. 2007). 
  The majority of conditional expression LVs is based on the Tet-dependent 
system. Early designs employed a binary strategy, which requires co-transduction 
with one vector driving constitutive expression of the regulatory protein and another 
with the gene of interest under control of a conditional promoter (Régulier et al. 
2002; Vigna et al. 2002; Johansen et al. 2002; Koponen et al. 2003).  These systems 
showed variable efficiencies because the rate of transduction of each vector was not 
the same in every cell. The use of multiple LVs also increases the risk of insertional 
mutagenesis. To circumvent this problem, inclusion of both components in a single 
LV construct was achieved, either by using two promoters or polycistronic cassettes.  
Both TetOn (Barde et al. 2006; Reiser et al. 2000) and TetOff (Kafri et al. 
2000) systems have been employed in single LV constructs. TetOff designs have the 
disadvantage that they require continuous administration of Dox for as long as the 
expression  needs  to  be  suppressed.  Hence,  this  model  is  only  useful  if  gene 
expression is to be maintained for a long time. TetOn systems have been used in 
several  models,  but  in  some  cases  they  appeared  to  display  a  poor  response  to 
physiological doses of the inducer drug  (Vogel et al. 2004). Barde et  al. (2006) 
compared  several  TetOn  LV  designs  and  showed  efficient  control  of  transgene 
expression  in  vitro  and  in  the  haemopoietic  system  of  mice.  More  recently, 
combination of a second generation TRE and introduction of an insulator seemed to 
decrease background expression and achieve good control in regulation of expression 
in the central nervous system (Xuebi et al. 2009).     124 
  Based on the existing evidence of improved systems of regulatable antigen 
expression, it was decided to study an inducible antigen expression model with LVs 
to  further  understand  the  mechanisms  involved  in  the  immune  response  they 
generate. 
5.1.2. Aims 
·  Test a model of inducible antigen expression in LVs in order to study the 
effects of the duration of antigen presentation on the immune response. 
 
·  Study  the  effects  of  LVs  on  the  activation  of  DCs  by  delaying  antigen 
expression. 
 
 
5.2.  Results 
5.2.1. Inducible transgene expression in DCs in vitro 
  In  order  to  set  up  a  model  of  regulatable  antigen  expression,  a  lentiviral 
construct described by Barde et al. was used.  In this TetOn system, expression of the 
gene of interest is controlled by a Tet-dependent transactivator (rtTA2
S-M2), which 
is  constitutively  expressed  from  a  second  promoter  within  the  same  vector  (Fig. 
2.1C).    This  vector  has  been  shown  to  control  gene  expression  in  cells  of  the 
haemopoietic system, with up to 100-fold induction of expression in the presence of 
doxycycline and only background levels in the non-induced state (Barde et al. 2006).  
  A cassette encoding GFP was cloned under control of the inducible promoter 
and tested in vitro in BMDCs (Fig. 5.2A-B). Although GFP expression was observed 
in up to 20% of the cells that were not treated with doxycycline, the presence of the 
inducer almost doubled the proportion of GFP
+ cells (Fig. 5.2A). The amount of GFP 
expressed—as reflected by the mean fluorescence intensity (MFI)—remained almost     125 
at background levels in non-induced cells and increased 3-5 times in the presence of 
Dox (Fig. 5.2B). 
  OVA expression was tested by Western blot in 293T cells, since the OVA 
antibody background in BMDCs difficulted the analysis. Figure 5.2C shows a dose-
dependent  induction  of  OVA  expression  in  the  presence  of  Dox.  In  its  absence, 
expression was only detectable at the highest concentration of LV. 
  These experiments show that doxycycline effectively induces expression of 
the gene under control of the regulatable promoter in DCs. However, there is some 
“leakiness”  in  the  system,  resulting  in  expression  of  the  transgene  even  in  the 
absence of the inducer.  
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5.2.2. Induction of antigen expression in vivo 
  To  determine  whether  upregulation  of  antigen  expression  resulted  in  a 
stronger immune response, the OVA-encoding TetOn LV was injected in mice at 
different  doses  by  subcutaneous  and  intravenous  routes.  An  IFN-￿  ELISPot  with 
OVA257-264 re-stimulation was performed 10 days after injection of the vector and 
continuous administration of Dox. 
  There was considerable variability among the mice injected intravenously. 
An  OVA-specific  CD8
+  T  cell  response  was  observed  both  in  the  groups  that 
received  Dox  and  in  controls,  probably  because  of  basal  OVA  expression  (Fig. 
5.3A). Only a small increase in the number of spots was observed when Dox was 
provided, which was comparable to that of a constitutively-expressing vector in all 
groups. 
A similar result was observed after subcutaneous injection.  In this case, the 
difference in the response between the induced and non-induced groups was more 
evident  at  low  doses  of  LV,  but  lower  than  the  response  observed  with  a 
constitutively-expressing vector (Fig. 5.3B). 
These results demonstrate that control of the expression of the antigen in vivo 
with this regulatable vector yields variable immune responses that do not necessarily 
correlate with the administration of doxycycline. This is probably because of the 
“leakiness” in the expression, also observed in vitro.  
5.2.3. Delayed antigen expression 
  The  effect  of  delayed  antigen  expression  was  tested  in  vivo  by  inducing 
expression of the vector 30 days after the LV was administered. This segregates the 
DC activation induced by the LVs from the actual antigen presentation. A low dose 
of LV was used to reduce the effects of basal expression. 
  An increase in the number of OVA-specific CD8
+ T cells was induced by 
Dox when provided immediately after LV administration, both in groups injected 
intravenously or subcutaneously (Fig. 5.4A-B). The response in mice injected iv was     128 
higher but still lower than in mice injected with a constitutively-expressing vector, 
probably because of the difference in the doses used. These results were reflected in 
the ability to lyse specific cell targets (Fig. 5.4C-D). However, delayed expression of 
the antigen 30 days after the LV was injected did not result in an immune response in 
any group (Fig 5.4). 
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5.3.  Discussion 
  Regulation  of  gene  expression  in  a  cell-specific  and  temporally-restricted 
manner remains a challenge in gene therapy.  Many of the approaches used so far 
have suffered either from unwanted expression or from poor inducibility. Several 
LV-based systems with regulatable promoters have been described (Stieger et al. 
2009).  In many of them, transduction with two vectors is necessary, resulting in 
variabile levels of expression. To avoid this problem, a Tet-On inducible system 
based on a single LV platform was used to study regulated expression of an antigen 
gene (OVA).  
Although the expression inducibility was observed in DCs, basal levels of the 
transgene were also present in the absence of Dox (Fig. 5.2). Since the amount of 
antigen required to elicit an immune response is minimal, this ‘leakiness’ resulted 
problematic when the vector was used in vivo. A very tight regulation is desirable in 
this  case,  but  tighter  systems  often  result  in  insufficient  expression  even  in  the 
presence of the inducing agent. 
  In vivo, basal expression of the antigen resulted in generation of an immune 
response even in the absence of the inducer. This was more evident at high doses of 
LV,  although  there  was  a  high  individual  variability.  As  shown  in  chapter  4, 
transcription  of  the  transgene  is  necessary  for  effective  immunisation  with  LVs. 
Thus,  it  is  unlikely  that  the  responses  observed  in  non-induced  mice  were  just 
because of co-purified protein. 
  To reduce this problem, a lower dose of LV was assayed both in the short and 
long  term.    A  larger  cytolytic  response  was  observed  in  mice  that  received 
doxycycline  immediately  after  injection  of  LV,  in  contrast  with  those  where  the 
doxycycline was started 30 days later. Results were more evident when the vector 
was administered intravenously probably because of the higher dose used.  
The absence of immune response after delayed antigen expression could be 
explained because at this time point, antigen presentation is not accompanied by an 
innate immune response. Therefore, a lower activation of DCs is expected, agreeing     133 
with the lower expression of co-stimulatory molecules observed in the transduced 
DCs after 30 days (Fig. 4.5). A way of confirming this hypothesis is by testing if 
activators of the innate immune system (e.g., poly I:C, CpG) could ‘rescue’ of the 
response to protracted antigen presentation.  
  Another possible explanation is that the antigen expression was insufficient in 
the long term. However, this is against the previous observation that the proportion 
of  transduced  cells  increases  over  time  and  with  the  transduction  of  dividing 
precursors (Table 3.3).   According to the latter, more transduced cells would be 
expected in the long term, since none or lower antigen expression would protect DCs 
from CTL elimination.  However, the dose of vector used in these cases was lower 
than the one employed in previous experiments, which means that fewer cells are 
expected to be transduced. It is also possible that transduction of DC precursors is 
only  achieved  at  high  doses  of  the  vector.    Quantification  of  mRNA  would  be 
necessary to clarify these questions and confirm if, even in the presence of transgene 
expression, activation of DCs is insufficient to generate an immune response in the 
long term. 
  An inducible antigen expression system would be a useful tool to study the 
effect of the duration of antigen presentation on the magnitude and quality of the 
immune response. LVs with inducible promoters have been used in models of gene 
therapy and for regulatable central expression of antigens in transgenic mice (Probst 
et al. 2003; Dresch et al. 2008), but not for conditional antigen expression in LV-
based vaccines. The model described here is limited because of the leakiness of the 
system. This  resulted in a high  variability that  made interpretation of the results 
difficult.  Further  improvements  in  the  design  of  the  vector  should  be  tested  to 
improve this model.  
Several  alternatives  have  been  evaluated  in  LVs  to  minimise  background 
expression of Dox-regulated systems. These include: (1) second generation TREs, in 
which the distances and positions of consecutive tetO sequence elements have been 
optimised; (2)  separation of expression cassettes with gene insulators, such as the 
chicken HS4 insulator (cHS4), that prevent positional interference of other promoters 
(Pluta et al. 2005; Xuebi et al. 2009); (3) the use of more complex vector designs. 
For  example,  Markusic  et  al.  used  a  single  LV  with  a  TetOn  system  and  an     134 
autoregulatory  loop,  achieving  high  viral  titers,  improved  induction  kinetics  and 
increased  induction  levels  (Markusic  et  al.  2005).  Szulc  et  al.  (2006)  have  also 
developed  a  Dox-controllable  LV  with  a  combined  tTA/KRAB  (TetOff)  or 
rtTA/KRAB (TetOn) complex. Expression from RNA polymerase II or III promoters 
can  be  regulated  by  this  system.  Combination  of  a  Tet-dependent  transactivator 
(rtTA) and silencer in the same construct also reduces the leakiness, but decreases 
the level of inducibility (Barde et al. 2006; Zhu et al. 2001). Alternatively, other 
regulatable  gene  expression  systems  dependent  on  other  drugs  or  Cre-Lox-based 
models could be tested.  
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CHAPTER 6 
6. FINAL DISCUSSION AND FUTURE DIRECTIONS 
  This thesis has explored the possible causes and implications of sustained 
antigen presentation following antigen gene delivery by LVs to APCs.  This work 
was based on the well established fact that gene transfer using LVs results in long-
lasting, stable gene expression, as has been shown in several animal models (Kim et 
al. 2009; Miccio et al. 2008; Kang et al. 2005b). Long-term gene expression had 
been  reported  in  DCs  in  the  spleen  following  systemic  administration  of  LVs 
(Esslinger et al. 2003; Kimura et al. 2007), in spite of the short life span of these 
cells (Kamath et al. 2000). Since there is considerable interest in the use of LVs as 
vaccine vectors, it was important to address the effects of long-term transduction of 
DCs both as an issue of vaccine efficacy and safety. This chapter summarises the 
main conclusions reached by this project, their practical implications and directions 
for future research on the topic. 
6.1.  Summary and conclusions 
  The  results  presented  in  this  thesis  have  demonstrated  that  intravenous 
administration  of  LVs  results  in  efficient  transduction  of  DCs  in  the  spleen, 
confirming findings of previous reports (Esslinger et al. 2003; Kimura et al. 2007; 
Palmowski  et  al.  2004).  Furthermore,  there  was  transduction  of  all  DC 
subpopulations, B cells and macrophages. Transduced  DCs, but not lymphocytes, 
persist for a longer period of time than the expected half life of these cells.  The 
evidence  obtained  suggests  that  this  probably  results  from  transduction  of 
proliferating precursors that give rise to a long-term supply of DCs. The fact that 
DCs are the predominant BrdU-labelled, transduced cell population argues for the     136 
transduction  of  a  committed  DC  progenitor  either  in  the  bone  marrow  or  in  the 
spleen (Naik et al. 2006; Liu et al. 2009).   
The  proportion  of  persistent  transduced  cells  was  smaller  when  the  LVs 
encoded OVA, a stronger immunogen, presumably because of immune killing of the 
antigen-bearing cells. Despite the elimination of these cells, there was persistence of 
antigen  presentation  that  stimulated  cognate  T  cells  even  3  months  later.  This 
suggests  that  it  is  possible  that  the  continuous  supply  of  transduced  cells  from 
dividing precursors counterbalances the elimination of antigen-expressing DCs by 
the  CTL  response.  The  remaining  population  of  transduced  DCs  stimulates 
proliferation  and  activates  antigen-specific  CD8
+  T  cells.  Protracted  antigen 
presentation also takes place outside the spleen, suggesting that transduction of DCs 
or  other  cell  types  in  other  organs  also  play  a  role.  These  include  long-lived 
macrophages and possibly non-professional APCs.   
Transduction  of  DC  precursors,  however,  does  not  necessarily  result  in 
effective T cell stimulation by its progeny, as these cells might not be sufficiently 
activated. Indeed, it was shown that the expression of costimulatory molecules in 
transduced DCs was lower in the long term as compared to the activated profile 
observed  immediately  after  LV  administration.  Additionally,  when  the 
administration of LVs was dissociated from the actual antigen expression using an 
inducible expression system, the immune response to the antigen was impaired.  
However, the long-term consequence of LV administration was immunisation 
rather than tolerance. This was demonstrated by activation of adoptively transferred 
transgenic CD8
+ T cells and by detection of a sustained endogenous CD8
+ T cell 
response,  capable  to  lyse  specific  targets.  Although  more  experimental  work  is 
necessary  to  show  the  effect  of  protracted  antigen  presentation  on  different 
lymphocyte  populations,  these  data  show  that  a  single  administration  of  LVs  is 
sufficient to induce a rapid and protective primary response and to generate effective 
memory and maintenance of a protective state.  
These  data  emphasise  the  utility  of  LVs  as  tools  for  immunotherapy. 
Persistent transduction of APCs also opens the opportunity to employ these vectors 
for long-term immunomodulation in other scenarios (e.g., autoimmune diseases, gene 
therapy, transplantation, chronic infections).     137 
6.2.  Limitations of the model 
This project was performed using OVA as a model antigen in mice as a proof 
of principle for persistent antigen presentation. Extrapolation of the results must take 
into account the differences between the mouse and the human DC systems and the 
possible effects of delivering other type of antigens.   
The  surface  markers  of  human  DC  subtypes  differ  from  those  in  mice, 
although  the  distinct  DC  subsets  have  been  paired  with  equivalent  murine 
counterparts  (Shortman  &  Liu  2002;  Banchereau  et  al.  2009).  However,  the 
ontogeny of DCs in humans is poorly understood. Human DCs can be generated 
from  CD34
+  CD38
-  haemopoietic  stem  cells  or  from  peripheral  blood  CD14
+ 
mononuclear  cells,  but  identification  of  committed  DC  precursors  has  been 
challenging given their low frequency, different markers from those known in mice 
and  the  obvious  impossibility  to  perform  reconstitution  experiments.  Local 
precursors in the spleen or peripheral lymphoid tissues, similar to those in mice, have 
not  been  identified  yet  (Mortellaro  et  al.  2009).  It  has  been  shown  that  LVs 
efficiently transduce haemopoietic stem cells (Sutton et al. 1999), but it is not known 
if downstream, committed precursors could also be transduced.  In spite of these 
differences, these results suggest the possibility of targeting human DC precursors 
with LVs. 
It would be important to evaluate the persistence of antigen presentation with 
clinically  relevant  antigens  from  pathogens  or  tumour  cells.  The  latter  are 
particularly  important  since  in  many  cases  TAAs  are  self-antigens.    The 
consequences of sustained presentation of a self-antigen must be explored, as it could 
result in autoimmunity. 
In  this  study,  the  effects  of  antigen  presentation  were  measured  through 
adoptive transfer of TCR-transgenic cells. With this method, an abnormally high 
frequency of naïve CD8
+ T cells is provided, which can activate DCs or provide their 
own help (Ruedl et al. 1999; Wang et al. 2001). Thus, it would be necessary to know 
the response of endogenous naïve and memory antigen-specific T cells to protracted 
antigen presentation.      138 
Finally,  the  route  of  administration  used  in  these  experiments  was 
intravenous.  It is more likely that a subcutaneous route will be used for clinical LV 
immunisation because it is more efficient (Lopes et al. 2008).  A different route of 
administration  can  result  in  targeting  of  different  cell  populations  and this  could 
change  the  duration  of  antigen  presentation.    Using  the  subcutaneous  route, 
expansion of TCR-transgenic T cells specific to the antigen has been shown for 21 
days, after which it seems to decline (Dullaers et al. 2006; Karwacz et al. 2009). 
6.3.  Considerations for the therapeutic application of LVs 
  As mentioned before, the possibility of extending antigen presentation for 
longer periods due to transduction of DC precursors must also be contemplated in 
humans.  LV targeting of an equivalent DC precursor in the human would allow 
sustained, potentially life-long, expression of the transgene in DCs. In the context of 
systemic gene delivery for gene therapy, this could be an obstacle since it could 
result in a sustained or delayed immune response against the therapeutic transgene. 
In contrast, it could be an advantage when the objective is to generate an immune 
response against the transgene. Inefficiency of some vaccines has been attributed to 
short  life  of  antigen  presentation.  Thus,  sustained  expression  of  antigen  could 
improve  vaccine  efficacy,  with  a  single  injection  being  sufficient  to  generate 
protective immunity without the need of boosting.  
DCs  can  also  be  genetically  modified  by  LVs  to  become  tolerogenic  by 
manipulating intracellular transduction pathways (Escors et al. 2008). In this case, 
delivery  of  a  self-antigen  together  with  tolerogenic  signals  to  appropriate  DC 
precursors could provide life-long therapy for autoimmunity. In this way, LVs offer 
the unique opportunity to tailor the immune response taking advantage of the ample 
functional plasticity of the DCs.     139 
6.4.  Future perspectives 
  Several questions arise from the work presented in this thesis that I consider 
deserve further investigation. In the first place, LV targeting of specific DC subtypes 
is important as in the past few years distinct functional characteristics have been 
identified for different DC subpopulations.  
Second,  it  would  be  important  to  study  the  kinetics  of  DC  precursors  to 
determine  for  how  long  transduced  progenitors  can  maintain  a  population  of 
genetically-modified DCs. Further  characterisation of these progenitors, including 
their phenotype and anatomic location, would require better isolation techniques and 
reconstitution  experiments.    This  would  allow  identifying  which  stages  of  DC 
development could be targeted by LVs, design vectors to target specific DC subtypes 
or de-target them from other haemopoietic lineages.  
The  immune  consequences  of  persistent  antigen  presentation  need  to  be 
studied in more detail. The results obtained here show that there is no tolerance to the 
transgene in the long term. This contrasts with results from other vaccination models 
where a short presentation of the antigen yields better immune response (Hovav et al. 
2007;  Radcliffe  et  al.  2007;  Finn  et  al.  2009;  Bergmann-Leitner  et  al.  2009). 
However, these studies have used DNA or adenoviral vector vaccines, where the 
mechanism of antigen presentation could be different. To investigate this with LVs, 
it would be necessary to isolate the persistent transduced DCs and characterise them 
ex  vivo.  This  is  a  challenging  task  because  of  their  low  frequency.    Another 
possibility could to generate a model where transgene expression in DCs can be 
controlled in time.  This can be done with an improved regulatable vector like the 
one tested here that would allow a tight control of antigen expression or targeted 
ablation of transduced DCs. 
6.5.  Towards a LV-based vaccine 
There is considerable interest in the use of LVs as vaccine vectors as they are 
efficient for delivery and expression of antigen genes in DCs in vivo.  The evidence     140 
suggests that their potential benefits outweigh the risks, especially for the treatment 
of serious illnesses like cancer or AIDS.  There are still more  challenges in the 
development  of  LV-based  vaccines,  including  production  up-scaling,  vector 
engineering, targeting of specific cells, co-expression of immuno-modulators and use 
of non-integrating LVs. This thesis has examined the duration and quality of the 
immune  response  induced  by  LVs,  highlighting  the  long-term  consequences  of 
transgene expression, which is highly relevant to all fields of therapy with LVs.     141 
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